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Abstract
Every year tens of millions worldwide suffer from cartilage damage, caused by
mechanical degradation, trauma or disease. Because of the lack of blood supply and low cell
concentration within the tissue, cartilage has very limited regenerative ability. Although current
treatments can provide symptomatic relief, the results vary greatly among individuals, and newly
formed tissue often does not duplicate the structure, composition or mechanical properties of
normal cartilage. Therefore, in recent years, tissue engineering has emerged as an alternative
therapy. Tissue engineering enhances the body's natural healing capacity by providing cells,
signaling molecules, and an environment in the form of a scaffold that is conducive to tissue
growth. This project has focused on the development of a tissue engineering scaffold for
cartilage regeneration. Disadvantages to current scaffolds include the fact that they require
surgery for implantation, and that they are difficult to mold to the exact shape of the defect site.
Hence, the motivation of this thesis is to develop an injectable scaffold that can be administered
in a minimally invasive manner, and that allows for scaffold formation in situ, naturally shaping
the construct into the shape of the defect, and thus promoting integration and stability
To this end, we have developed a thermoresponsive injectable scaffold for cartilage tissue
engineering. The scaffold was injected as a liquid at room temperature, and gelled at the target
site in response to the change to body temperature, resulting in a biocompatible, bioresorbable
substrate for tissue growth. Our approach involved suspending thermoresponsive liposomes,
which encapsulated a crosslinking agent, in a polymer solution. At room temperature, the
crosslinking agent was separated from the polymer by the lipid membrane, hence the precursor
solution remained a liquid and injectable. Upon injection and exposure to body temperature, the
lipids experienced a phase transition, which significantly increased the membrane permeability
and led to the release of the crosslinking agent and reaction with the polymer, forming a
networked scaffold. The scaffold system that we have chosen is a hyaluronic acid-tyramine
system (HA-Tyr) that crosslinked in the presence of H20 2 and horseradish peroxidase (HRP) to
form a hydrogel. Since HA, Tyr, H20 2 and peroxidases all occur naturally in the body, scaffold
formation could take place with minimal toxicity and in the presence of cells as well as in situ. In
order to impart temperature sensitivity to this system, HRP was encapsulated within liposomes,
and it was shown that HRP was successfully retained at 250 C and released at 370C. Upon
liposome addition to the HA-Tyr/H20 2 solution, the precursor solution remained a liquid for
hours at 250C, yet gelation could be induced within minutes when exposed to 370 C. Furthermore,
it was shown that gelation times could be adjusted to meet various clinical needs by modulating
HRP encapsulation, liposome concentration and HA-Tyr concentration.
In order to test the potential of the HA-Tyr system for cartilage production, porcine
chondrocytes were encapsulated within HA-Tyr/H20 2/HRP hydrogels and implanted
subcutaneously in mice. Harvested constructs were shown to achieve a GAG content of 1.2 wt%
and demonstrated 40% of the collagen content of normal articular cartilage. Matrix production
was found to be influenced by the initial cell density, scaffold degradation rate and Type II
collagen concentration. The means of HRP delivery, whether by simple addition or through
thermoreponsive liposomes, was not shown to have an effect on matrix production. Injected
scaffolds were shown to achieve GAG and collagen levels similar to that of implanted scaffolds.
As signaling molecules have been demonstrated to be potent chondrogenic inducers,
PLGA-hydroxyapatite nanocomposite microparticles were utilized for the controlled delivery of
TGF-31 and IGF-1. The rate of growth factor release was modulated by the molecular weight of
PLGA within the microparticles; increasing molecular weight led to decreasing release rate. The
nanocomposite microparticles were encapsulated within HA-Tyr/H202/HRP/chondrocyte
constructs, which were then implanted subcutaneously in mice. Growth factor-induced
enhancement of GAG and collagen production was found to be determined by the release rates
of TGF-31 and IGF-1, multifactor release, and the dosage of nanocomposite microparticles.
Injection of the microparticles with an HA-Tyr/H202/HRP liposome/chondrocyte/collagen
solution also showed that the microparticles did not interfere with in situ scaffold formation, and
could induce significant improvements to GAG and collagen production in the injectable system.
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microparticles and 10 mg/mL of TGF-P I -loaded PLGA-HAP
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(o) 6 kDa and 24 kDa, (+) 24 kDa and 6 kDa, and (o) 24 kDa and 24 kDa,
respectively, and (e) with no particles. 91
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blue content within HA-Tyr/H20 2/HRP/chondrocyte constructs with 40
mg/mL of IGF-1-loaded PLGA-HAP nanocomposite microparticles and
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with PLGA MW's of (a, A) 6 kDa and 6 kDa, (b, m) 6 kDa and 24 kDa, (c,
*) 24 kDa and 6 kDa, and (d, o) 24 kDa and 24 kDa, respectively, and (e,
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Chapter 1 - Background and Motivation
1.1 Cartilage Regeneration
Every year tens of millions worldwide suffer from cartilage damage, and over 1 million
surgical procedures in the United States alone involve cartilage reconstruction [1,2]. The main
function of cartilage is to serve as a shock absorber and lubricant in the joints, but mechanical
degradation, trauma, or diseases, such as arthritis, can lead to the irreversible loss of cartilage's
structure and function [3]. This, in turn, results in a great deal of pain, swelling, limited mobility,
and eventually joint deformation. The problem is that, unlike bone and skin, cartilage has very
limited regenerative ability, largely due to the lack of blood supply and low cell concentration
within the tissue [4, 5, 6]. Current treatments include lavage, subchondral bone penetration,
transplantation, or implantation of prosthetics [7]. The disadvantages of these therapies arise
from infliction of additional injury, donor site morbidity, limited donor supply, and prosthetic
durability [4, 8, 9]. In addition, although these treatments can provide symptomatic relief, any
newly formed tissue has a limited life span because it does not duplicate the structure,
composition and mechanical properties of natural articular cartilage [3].
1.2 Cartilage Tissue Engineering
In recent years, tissue engineering has emerged as an alternative therapy. Tissue
engineering involves the construction of a biological device that either elicits tissue regeneration
or replaces damaged tissue. This is generally accomplished by three components: (1) patient or
donor cells, (2) regulators that guide the regenerative activity of the cells, and (3) a scaffold that
acts as a delivery vehicle for the cells and regulators, as well as a substrate for tissue growth [8].
By introducing a cell-seeded matrix supplemented with signaling molecules that promote tissue
synthesis, the low cell concentration and avascular nature of cartilage can be addressed. This
method may enhance the healing capacity within the defect site without the need to augment
injury, use prosthetics and, perhaps with the advent of stem cell technology, sacrifice healthy
cartilage.
Several studies have already shown the feasibility of tissue engineering in cartilage
restoration. Perhaps the most established tissue engineering solution today is the injection of
autologous cells into a cartilaginous defect, which is subsequently covered by a periosteal flap.
The advantage of this solution lies in the in vitro expansion of a relatively small quantity of cells,
isolated from non-load-bearing cartilage, which are re-implanted to induce regeneration by
increasing the local cell concentration in the defect site. Results, in particular long-term findings,
have been controversial, however, and in a recent study in canines, cartilage had begun to
degrade 12-18 months post-implantation [6, 8, 10]. One possible reason is the leakage of
chondrocytes out of the sutured flap, particularly upon application of mechanical loads [5].
Another possibility is the uneven tissue growth due to the imbalanced distribution of cells post-
implantation, with chondrocytes accumulating at an edge dictated by gravity. It is proposed that
these issues can be addressed by the incorporation of a scaffold. Cells seeded on a matrix may be
less likely to escape the defect site, and the spatial distribution of cells can be more easily
controlled. Lee et al. have demonstrated that chondrocyte-seeded Type II collagen sponges
implanted in cartilage defects resulted in greater reparative tissue than untreated defects or cells
implanted alone [ 11].
1.3 Injectable Scaffolds
Significant research has been devoted to the development of suitable scaffolds as the
matrix plays a key role in tissue engineering. The scaffold must act as a temporary extracellular
matrix (ECM), support and guide cell growth, and provide mechanical support [12]. In order to
meet these requirements, the scaffold needs to possess the following properties: (1) be non-toxic
and non-inflammatory, (2) promote cell stability and tissue production, (3) possess
interconnecting pores that allow cell migration and tissue growth, (4) be bioresorbable,
degrading either during or after healing, (5) be mechanically robust, and (6) be capable of being
fabricated to fit the shape of various defect sites [13, 14]. The scaffold materials most commonly
used for cartilage are either natural polymers, such as hyaluronic acid (HA), collagen, alginate,
agarose and fibrin, or synthetic polymers, such as poly(glycolic acid), poly(lactic acid) and
poly(ethylene glycol) (PEG) [3, 6, 8, 11, 12, 15, 16, 17, 18, 19]. Chondrocytes grown on such
scaffolds in vitro and in vivo have synthesized tissue resembling articular cartilage histologically
and mechanically [20, 21].
Currently, several limitations remain in the development of an appropriate scaffold. First,
implantation of the scaffold generally requires invasive surgery, which inherently involves risks,
such as infection and failure to heal [22]. Secondly, it is difficult to mold a material to perfectly
fit a defect site [14]. A poorly fitted scaffold can result in failure of the newly formed tissue to
integrate with the host tissue, which may subsequently lead to dead space and implant instability.
Dead space can cause fluid accumulation and chronic inflammation, while implant instability can
cause micromotion, producing forces at the construct interface [23 ]. Both result in the
degradation and limited lifetime of the reparative tissue.
In order to address these issues, injectable scaffolds have been investigated as a possible
approach to tissue engineering. This method is based on the injection of a liquid that cures in the
defect site in response to a stimulus. The liquid is generally composed of a soluble monomer or
polymer that forms a hydrogel by crosslinking, polymerization or phase transition. Gelation can
be induced by various stimuli, including a change in temperature or pH and application of high-
energy light [18, 24, 25, 26, 27]. This approach would not only eliminate the need for surgery
and potentially reduce patient recovery time, but also enable the scaffold to take the shape of the
defect as scaffold formation occurs in situ [28]. Integration of the scaffold with the existing
tissue would be improved, due to the intimate contact of the polymer with the surrounding tissue
during scaffold formation, and the mechanical interlocking that occurs as a result of surface
microroughness [18].
Previous research has shown the feasibility of this approach. Elisseeff et al. have
demonstrated the potential of in situ scaffold formation by transdermal photopolymerization for
cartilage repair [18, 19]. Although the newly formed tissue has been shown to histologically
resemble cartilage, photopolymerization is limited by the penetration depth of high-energy light.
Ultraviolet (UV) light, for example, has been shown to have a penetration depth of only 2 mm in
human skin, restricting the defect sites that can be treated by transdermal photopolymerization
[18]. Furthermore, high-energy light is known to cause cell and tissue damage [29, 30].
1.4 Research Objectives
To avoid the use of radiation, the objective of our research is to design a scaffold such
that solidification can be induced by an environmental stimulus that is constant throughout the
body, namely temperature. Since the curing process is initiated simply by exposing the scaffold
to a physiological condition, the scaffold could potentially be induced to gel anywhere in the
body. The ideal characteristics of the scaffold include:
1. Stability as a liquid at room temperature - to allow sufficient working time for clinicians.
2. Rapid gelation at body temperature - to prevent diffusion out of the defect and minimize
waiting time.
3. Tunable gelation kinetics - to allow clinicians to decide upon the working and setting times
appropriate for various applications and situations.
4. Effective promotion of cartilage production.
Other desirable properties of the scaffold include porosity, biodegradability, bioactivity and ease
of manufacture.
To achieve the research objectives, the following approach was taken:
1. Synthesis of thermoresponsive microcapsules that encapsulate a crosslinking agent (Chapter
2).
2. Combination of microcapsules with polymer solution to form a precursor solution that is
injectable as a liquid at room temperature (250 C), and cures to form a scaffold at the target
site in response to the change to body temperature (370 C) (Chapter 2).
3. Encapsulation of cells and evaluation of efficacy of the scaffold for cartilage production in
vivo (Chapter 3).
4. Incorporation of growth factor carriers for the controlled release of TGF-P1 and IGF-1 to
enhance cartilage synthesis by cells (Chapter 4).
1.5 Thermoresponsive Liposomes for Thermally Triggered Injectable Scaffolds
Our approach for creating a thermally triggered injectable scaffold involves the
dispersion of thermoresponsive liposomes (which encapsulate a crosslinking agent) within a
polymer solution. At room temperature, the crosslinking agent and polymer are segregated from
each other, and the precursor solution remains a liquid. At body temperature, however, the
crosslinking agent is released, causing the polymer to form a three-dimensional network and the
precursor solution to cure. Encapsulating the crosslinking agent potentially enables the injection
of scaffolds that would otherwise require implantation, eliminates the need for co-injections
(which can lead to inhomogeneous constructs), and prolongs the working time of pre-mixed
systems significantly.
Liposomes are composed of amphiphilic molecules that self-assemble into a spherical
bilayer around an aqueous core. They were chosen to carry the crosslinking agent because they
are biocompatible, versatile encapsulating agents that have been studied extensively for the
delivery of various therapeutic agents [31, 32, 33, 34]. Furthermore, many phospholipids are
known to experience a gel-to-liquid phase transition at a given temperature, where the alkyl
chains experience a trans-to-gauche conformational change [35, 36]. During this process, the
membranes of liposomes, composed of such lipids, become more disordered, significantly
enhancing membrane permeability and allowing the encapsulated molecules to be released from
the liposomes. In order to achieve the thermally triggered scaffold system described above, the
crosslinking agent was encapsulated within liposomes with a phase transition temperature near
370 C. The mechanism of gelation is depicted in Figure 1.1.
Systematic modulation of gelation kinetics may be possible by changing variables that
affect the crosslinking reaction rate, such as the polymer concentration, the loading of
crosslinking agent within the liposomes, and the liposome concentration.
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Figure 1.1. The precursor solution is a liquid at room temperature. Exposure to body temperature
results in the release of the crosslinking agent, which subsequently leads to polymer crosslinking
and scaffold formation.
Several phospholipids experience phase transition temperatures in the range of body
temperature, and can be blended to achieve an overall phase transition near 370 C. Possible lipid
candidates include dimyristoylphosphatidlycholine (Tm = 23°C), dipalmitoylphosphatidlycholine
(Tm = 41 C), dimyristoylphosphatidylglycerol (Tm = 230C), dipalmitoylphosphatidylglycerol (Tm
= 410 C), dimyristoylphosphatidylserine (Tm = 35 0 C), dilauroyl phosphatidic acid (Tm = 310C),
dimyristoyl phosphatidic acid (Tm = 500 C), dilauroylphosphatidylethanolamine (Tm = 29 0 C), and
dimyristoylphosphatidylethanolamine (Tm = 500 C) [37].
This platform can be applied to impart temperature sensitivity to a broad scope of
polymer crosslinking agent or monomer catalyst systems. Candidates for the
polymeric/monomeric component and their respective crosslinking agents/catalysts include
collagen and lysyl oxidase, elastin and lysyl oxidase, alginate and Ca2+, polyethylene oxide-
dimethacrylate and 1-hydroxycyclohexyl phenyl ketone, fibrin and thrombin, fibrinogen and a-
transglutaminase, and biotinylated polymers and avidin [18, 19, 27, 38, 39, 40, 41, 42].
HA is an attractive scaffold candidate as it is one of the main components of the cartilage
ECM, and would therefore mimic the natural tissue environment [41]. Moreover, it is a highly
hydrophilic polysaccharide that contributes to the high Young's modulus and load-bearing
abilities of cartilage, and has been shown to be important in cartilage homeostasis [23, 43, 44].
Recently, a HA-tyramine (HA-Tyr) system was developed by Kurisawa et al., in which tyramine
groups were conjugated onto a HA backbone [45]. In the presence of hydrogen peroxide (H20 2)
and horseradish peroxidase (HRP), the tyramine groups react with each other to form crosslinks
between and within the HA polymer, which subsequently forms a hydrogel network (Figure 1.2).
Whereas other crosslinking methods often employ relatively toxic reactions such as carbodiimide
coupling and esterification, tyramine, H20 2 and peroxidases all naturally occur in the body,
achieving network formation without sacrificing the biocompatibility of HA [46, 47, 48, 49].
This enables curing to occur in the presence of cells and tissue, making this system a promising
candidate as an injectable scaffold. Furthermore, temperature sensitivity can be achieved by
pairing the HA-Tyr polymer with thermoresponsive liposomes, in which the crosslinking agent,
HRP, can be encapsulated.
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Figure 1.2. Crosslinking reaction of HA-Tyr in the presence of HRP and H20 2.
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Chapter 2 - Liposomal Encapsulation of Horseradish Peroxidase for Thermoresponsive
Hyaluronic Acid-Tyramine Scaffold
2.1 Introduction
2.1.1 Thermoresponsive Materials
Several methods have been investigated for the stimuli-responsive release of proteins
from particles or microcapsules. In many of these cases, polymers are grafted into the pores of a
polymer shell and serve as a gate. In the resting state, the capsule encloses the protein because
the grafted polymer covers the pores and limits permeability. Upon exposure to an external
stimulus, such as ionic strength, light, oxidoreduction, or pH, the polymers would experience a
phase change or shift in hydrophobicity, shrink and release the contents of the particle [1, 2, 3, 4,
5 ]. Okahato et al. and Lee et al., for example, grafted poly(methacrylate) (PMA) and
poly(acrylic acid) into the pores of a nylon membrane to synthesize capsules whose membrane
permeabilities were controlled by pH [1, 2]. Ito et al. grafted poly[3-carbamoyl-l-(p-
vinylbenzyl)pyridium chloride] onto a porous membrane, and showed that release could be
induced by the switch from an oxidizing solution (H20 2) to a reducing solution (Na2S20 4) [3].
Similar methods that utilize polymers that respond to ionic strength and UV light have also been
explored [4, 5].
The disadvantage of these systems lies in the fact that the materials, such as PMA, are
generally non-biodegradable, which would likely result in the material's remaining in the body
for extended periods and increase the possibility of a foreign body response [6]. In addition, the
grafting processes could involve complex and expensive synthesis procedures, such as glow
discharge or plasma grafting. Furthermore, many of these stimuli could affect the viability of the
cells and potentially result in local cell necrosis. Use of pH-responsive delivery, for example,
requires the injection of material under conditions either more basic or acidic than physiological
pH, which has the potential to cause local tissue necrosis. Exposure to strong oxidizing/reducing
agents, UV light or osmotic stresses is also widely known to cause cell death [7, 8, 9].
Thermoresponsiveness has been chosen for this study because temperature change is a
milder stimulus and because there is a convenient and substantial gap between room temperature
(25 0 C) and body temperature (370 C). Several studies have explored the synthesis of
thermoresponsive microcapsules for the release of proteins, with poly(N-isopropylacrylamide)
(NIPAAM) perhaps being the most common system employed. NIPAAM demonstrates a lower
critical solution temperature (LCST) just below body temperature, where the hydrophobicity of
the material increases and the polymer precipitates out of solution to form a hydrogel [10].
Similar to that described above, several studies have shown the ability to graft NIPAAM into the
porous membrane of capsules [2, 11, 12, 13]. At room temperature, NIPAAM covers the pores
and blocks the passage of the contents out of the capsule. At body temperature, the volume of
NIPAAM dramatically decreases, opening the pores and allowing for passage. The disadvantage
of these systems lies again in the inability of NIPAAM to degrade in the body.
In this study, we have chosen hyaluronic acid-tyramine (HA-Tyr) as our hydrogel system
because hyaluronic acid (HA) is biocompatible, biodegradable and non-immunogenic. The HA-
Tyr system, developed by Kurisawa et al., consists of the HA polymer, onto which tyramine
groups are conjugated [23]. The tyramine groups react with each other in the presence of H20 2
and horseradish peroxidase (HRP) to form a hydrogel network that can be used as a tissue
engineering scaffold. Since each reactant occurs naturally in the body, the scaffold formation
takes place with minimal toxicity.
In order to impart temperature sensitivity to the HA-Tyr system, we have encapsulated
the crosslinking agent, HRP, into thermoresponsive microcapsules. By segregating HRP from
HA-Tyr/H20 2 at room temperature, the mixture would remain as a liquid and injectable through
a syringe. Upon injection into defect site and exposure to body temperature, the microcapsules
would release HRP, resulting in the subsequent reaction between HRP and HA-Tyr/H20 2 and the
formation of a hydrogel scaffold.
Specifically, we have encapsulated HRP within thermoresponsive liposomes. Liposomes
have been chosen in this study because they are biocompatible and biodegradable materials that
have been widely studied for drug and gene delivery [14]. They have been shown to be stable in
the body and versatile encapsulating agents, with the ability to successfully hold and deliver ions
(e.g. Ca 2+), cancer therapeutics (e.g. doxorubicin), as well as antifungal compounds (e.g.
amphotecerin) [14, 15, 16]. Furthermore, temperature sensitivity can be achieved by the
appropriate choice of phospholipid. Many phospholipids undergo a phase transition at the main
lamellar chain-melting phase transition temperature, Tm, above which the alkyl chains undergo a
trans-gauche transition (Figure 2.1) [17]. In the gauche state, the lipids in the bilayer become
disordered, and permeability of the membrane significantly increases, permitting its contents to
be released into the environment. Dipalmitoyl-phosphatidylcholine (DPPC) (Tm = 410C) and
dimyristoylphosphatidylcholine (DMPC) (Tm = 230C) were combined together to form
liposomes with an overall Tm just below the body temperature, 370C.
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Figure 2.1. Trans-gauche transition of phospholipids: (.) phospholipids head and (,) alkyl tail.
2.1.2 Conventional Methods for Liposome Preparation
Several methods for encapsulating proteins and enzymes within liposomes have been
explored [18, 19]. Most approaches begin with the deposition of a lipid film on a surface, which
is then hydrated with an enzymatic solution. The mixture is heated above Tm and vortexed such
that the lipid film lifts off the surface to form liposomes around the enzyme solution. This
process can be followed by a variety of steps, such as sonication, extrusion, repeated freeze-
thawing, or ethanol addition (to induce interdigitation), to control size distribution and enhance
entrapment efficiency.
Various methods that employ organic solvents have also been studied [20, 21]. Reverse-
phase evaporation, for example, involves dissolving the lipid in a water-miscible organic solvent
with a low boiling point. Upon addition to an aqueous enzyme solution, a reverse emulsion is
formed with the aid of vortexing and/or sonication. The solvent is then removed under reduced
pressure to form a dispersion of vesicles with aqueous cores that contain the enzyme. The
ethanol injection method is similar, except that an ethanol/methanol solution containing the lipid
is injected into the aqueous enzyme solutions to form vesicles, in which with enzyme are
entrapped.
2.1.3 Dehydration-Rehydration Vesicle Method
The dehydration-rehydration vesicle (DRV) method was chosen for the encapsulation of
HRP primarily with the aim of preventing enzyme denaturation. Developed by Gregoriadis et al.
[22], this technique involves mixing blank pre-formed liposomes with the enzyme of interest at
room temperature (Figure 2.2). This mixture is then freeze-dried and rehydrated. During the
freezing and lyophilization steps, the liposome vesicles are destabilized, causing many to deflate
and merge with neighbors to form lipid sheets between which HRP is sandwiched. Upon
rehydration, the lipids would re-form liposomes, many of which have fused with their neighbors
around the HRP, effectively encapsulating HRP within the new vesicles. This method avoids
exposure of HRP to high temperatures, organic solvents and repeated freeze-thaw cycles that are
employed in other liposome encapsulation procedures, and that are known to denature proteins
and reduce enzymatic activity.
Figure 2.2. Schematic of the DRV method for preparing HRP liposomes.
2.2 Experimental
2.2.1 Conjugation of Tyramine to Hyaluronic Acid Backbone
HA-Tyr conjugation was performed as described by Kurisawa et al. [23]. Briefly, Tyr
was covalently attached to the HA (90-150 kDa) backbone by a reaction with N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS).
Unreacted Tyr and the by-products of the reaction were removed by dialysis. Tyr substitution
was verified by nuclear magnetic resonance (NMR) spectroscopy, and ranged from 8% to 9%.
HA and EDC were purchased from Lifecore and Alfa Aesar, respectively. Tyr and NHS were
purchased from Sigma-Aldrich.
2.2.2 Synthesis ofLiposomes
Liposomes were synthesized with varying concentrations of DPPC, DMPC and
cholesterol. HRP was encapsulated by the DRV method [22]. The lipid-cholesterol mixture was
dissolved in chloroform, which was then evaporated to form a film in a round-bottom flask. The
film was incubated with deionized water at 500 C for 30 min with intermittent vortexing. The
solution was sonicated with a probe-tip sonicator at 550 C for 30 min or until optically transparent.
After the solution had cooled to room temperature, an equal volume of enzyme solution was
added. The mixture was then frozen and freeze-dried. The liposomes were rehydrated with
phosphate buffer solution (PBS), and incubated at room temperature for 30 min. Unencapsulated
HRP was then rinsed off by repeated centrifugation (2500g, 1 min). The lipids, cholesterol and
PBS were purchased from Avanti Polar Lipids, Alfa Aesar and VWR, respectively. HRP and all
other chemicals were purchased from Sigma-Aldrich.
2.2.3 Measurement ofHRP Liposome Release
HRP release was measured by adding PBS to a given volume of liposomes. The mixture
was then incubated for a set amount of time at either room temperature or 370 C. The liposomes
were then centrifuged (20000g, 10 min) into a pellet, and the HRP concentration in the
supernatant was measured calorimetrically with the Amplex Red dye (Invitrogen) at 560 nm.
HRP liposome release was measured in terms of units of enzymatic activity derived from each
mL of liposomes (corresponding to - 300 mg of phospholipids).
2.2.4 DSC ofLiposomes
Liposomes (- 5 mg) prepared as described in Section 2.2.2 were added to aluminum
hermetic pans. Differential Scanning Calorimetry (DSC) was conducted on a TA Instrument
Q100 at a ramp rate of 100C/min.
2.2.5 Measurement ofLiposome Size
Liposomes were suspended in PBS, and their sizes were characterized with a Coulter
counter (Beckman Coulter Z2) for 2-6 pm, 6-10 Cpm and 9-30 tm. The liposome size was
calculated as the number average diameter.
2.2.6 Measurement of Gelation Kinetics
Hydrogels were formed by adding HRP liposomes to HA-Tyr/H20 2 (5 wt%, 5 tL per 25
mg of HA-Tyr) solutions. The gelation of the hydrogel networks was studied by oscillatory
rheometry on a TA Instrument AR 2000. HA-Tyr/H20 2/HRP liposome solutions were pipetted
onto a Peltier plate (set at 200C or 370C) upon which a 60-mm, 20 cone was lowered.
Measurements were obtained at a controlled strain of 1% and at a frequency of 1.0 Hz. The point
at which the storage modulus (G') and the loss modulus (G") intersected was considered the gel
point. G' values ofhydrogel were taken after 12 h, by which time G' had reached a plateau.
HRP deactivation was measured by incubating HRP in various solutions for 1 h at room
temperature. HRP activity was then measured calorimetrically with the Amplex Red dye. HRP
deactivation was calculated as:
Deactivation = 1 - (Activityx)/(ActivityH 2o)
where ActivityH2o was assumed to be the enzymatic activity of HRP in H20 (which
corresponded to the least deactivation or the maximum activity), and Activityx was the enzymatic
activity in solution x.
2.2.7 In Situ Gelation Study
Sterile HRP liposomes, aseptically prepared as described in Section 2.2.2., were
combined with sterile-filtered HA-Tyr (25 mg/1.5 mL of PBS)/H 20 2 (5 wt%, 5 jtL per 25 mg of
HA-Tyr) solution. The mixture was then injected subcutaneously into the dorsum of a BALB/c
mouse. The mouse was sacrificed after - 2 h, and the gel that had formed was harvested and
analyzed.
2.3 Results and Discussion
2.3.1 Modulation ofHRP Encapsulation within Liposomes
Following the DRV method, HRP liposomes composed of DPPC and DMPC were
prepared such that HRP remained encapsulated within the liposome at 25
0 C, and was released
rapidly at 370C (see Figure 2.3.2.3).
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Figure 2.3. Thermally triggered HRP release from liposomes at (A) 25°C and (0) 370 C.
Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2
mg/mL of HRP, 30-min sonication, -200 C freezing, and rehydration volume ratio = 0.1.
In order to synthesize liposomes that could be thermally triggered at body temperature,
DPPC and DMPC were chosen. By blending the two at the appropriate ratio, an overall phase
transition temperature just below 370 C could be achieved. As shown in Figure 2.4, an increase in
DPPC:DMPC weight ratio increases the phase transition temperature since TmDppC > TmDMPC. An
increase in the DPPC:DMPC weight ratio decreased the permeability of HRP at 37
0 C (Figure
2.5). The overall Tm should be a few degrees below 370 C to allow for effective release at 370C.
Otherwise, there would not be sufficient energy to disorder the alkyl chains significantly for
complete HRP release at 37C.
Cholesterol was added to modify bilayer fluidity and decrease enzyme leakage at room
temperature [19]. The addition of cholesterol, however, was found to do little for room-
temperature stability and actually decreased HRP encapsulation and liposome size (Figure 2.6.
2.6). Similar results were shown by Moribe et al.; the encapsulation efficiency of nystatin was
decreased with the incorporation of cholesterol in liposomes that were synthesized by repeated
freeze-thaw cycles [24]. Cholesterol is known to rigidify and stabilize liposome membranes, but
the increased stability also hinders the fusion of liposomes during the freezing and dehydration
process [25, 26]. Cholesterol is also shown to prevent the fusion of liposomes by decreasing the
zeta potential, and thereby increasing repulsion between the vesicles [25]. However, this process
of liposome fusion was critical in the DRV process for the HRP encapsulation. The lower extent
of fusion was also corroborated by the size of the resulting liposomes. Prior to freeze drying,
single unilamellar vesicles (SUV's) have a size of 20-50 nm [19, 27]. After rehydration, the
liposomes became much larger due to fusion of neighboring liposomes. The resulting size could
thus be seen as a measure of the degree of fusion. The smaller liposome size with the
incorporation of cholesterol confirmed the reduced degree of fusion, which resulted in a lower
HRP encapsulation efficiency.
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Figure 2.4. DSC curves of HRP liposomes synthesized wit
weight ratio = (-) 2.3, (--) 3.0 and (---) 4.0), 2 mg/mL of HR]
and rehydration volume ratio = 0.1.
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Figure 2.5. Thermally triggered HRP release from liposomes at (A,m,*) 25 0 C and (0,o,*) 370 C.
Liposomes were synthesized with 60 mg/mL of lipid (DPPC/DMPC weight ratio = (A,0) 2.3,(.,o) 3.0 and (*,*) 4.0), 2 mg/mL of HRP, 30-min sonication, -20 0 C freezing, and rehydration
volume ratio = 0.1.
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Figure 2.6. Effect of the cholesterol concentration on (m) the total HRP release from liposomes
after 1 h at 370C, and (+) the liposome size. Liposomes were synthesized with 20 mg/mL of lipid
(DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication, -200 C freezing, and
rehydration volume ratio = 0.1.
Figure 2.7 shows that as lipid concentration increased, HRP entrapment increased. This
was due to the increase in contact between the HRP and lipid vesicles. An increase in lipid
concentration increased the probability of contact between HRP molecules and lipid sheets,
thereby increasing the total encapsulation during vesicle fusion.
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Figure 2.7. Effect of the lipid concentration on the total HRP release after 1 h at 37°C.
Liposomes were synthesized with various lipid concentrations (DPPC:DMPC weight ratio = 2.3),
2 mg/mL of HRP, 30-min sonication, -20'C freezing, and rehydration volume ratio = 0.1.
Freezing and dehydration stresses can lead to significant denaturation of proteins during
liposome synthesis due to ice-induced unfolding and water removal from the protein's hydration
shell [28, 29]. Therefore, as shown in Table 2.1, the means by which the enzyme/liposome
solutions were frozen, which determined the rate of cooling, was important in controlling the
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enzymatic activity recovered. The slower the freezing rate, the less the enzyme would be
damaged during synthesis. In addition, the freezing process was a key factor in liposome fusion
and HRP encapsulation. When frozen under liquid nitrogen, the freezing process might occur too
quickly and inhibit liposome fusion, subsequently lowering HRP encapsulation. This was
evidenced by a smaller liposome size.
Table 2.1. Effect of the freezing method on the total HRP release after 1 h at 370 C and the
liposome size. Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio
= 2.3), 2 mg/mL of HRP, 30-min sonication, and rehydration volume ratio = 0.1.
HRP Release Liposome SizeFreezing Method (Unit/mL of Liposome) (pm)
Liquid Nitrogen 89.6 11.5
-200 C Freezer 108.0 15.3
Sonicating the liposomes prior to freezing was found to increase the enzyme
encapsulation (Figure 2.8). The sonication step converted the multi-lamellar vesicles (MLV's)
with an onion-like structure into small SUV's. Sonication broke up the liposome agglomeration
and dispersed the vesicles homogeneously within the solution, increasing the interaction between
the lipid and HRP prior to freeze drying, and thereby improving HRP encapsulation.
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Figure 2.8. Effect of the sonication time on (o) the total HRP release after 1 h at 370 C and (0) the
liposome size. Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio
= 2.3), 2 mg/mL of HRP, -20 0 C freezing, and rehydration volume ratio = 0.1.
It was also found that varying the rehydration volume ratio (volume of PBS added during
rehydration/volume of initial liposome solution) greatly affected the final HRP encapsulation
(Figure 2.9). During the rehydration process, the lipids blanketed the surrounding solution to
form liposomes. A rehydration volume ratio of zero, i.e. no incubation time, was not favorable,
as this would not give the liposomes time to re-form prior to washing by centrifugation. However,
increasing the volume of solution used for rehydration would dilute the HRP concentration
within each liposome. The optimal rehydration volume ratio was found to be 0.1.
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Figure 2.9. Effect of the rehydration volume ratio on the total HRP release after 1 h at 370C.
Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2
mg/mL of HRP, 30-min sonication, and -200 C freezing.
The HRP release at 370C could also be tuned by the initial HRP concentration of the
solution added to the blank liposomes prior to freezing. Figure 2.10.2.10 shows that as the HRP
concentration in the precursor solution increased, the HRP encapsulated increased. However,
above a HRP concentration of 2 mg/mL in the precursor solution, the protein (which also has
surfactant properties) would destabilize the liposomes and cause leakage in the membrane,
leading to lower HRP encapsulation. Previous research has also shown that the presence of
proteins can perturb the lipid bilayer, resulting in leakage of the liposomes' contents [30, 31 ].
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Figure 2.10. Effect of HRP concentration in the precursor solution on the total HRP release after
1 h at 370 C. Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio -
2.3), 30-min sonication, -20 0 C freezing, and rehydration volume ratio = 0.1.
2.3.2 Modulation of Gelation Time
When HRP-containing liposomes were suspended in the HA-Tyr/H20 2 solution and
heated to 37C, the elastic modulus, G', began to increase within 3 min, indicating the onset of
gelation (Figure 2.11). The gel point was reached in - 7 min at 370 C. On the other hand, the
solution remained as a liquid for over several hours at 200C, and the magnitude of G' remained
small and constant over time. This behavior and time frame reflected the HRP release observed
in Figure 2.3.2.3.
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Figure 2.11. G' of HA-Tyr/H 20 2/HRP liposome solution at (-) 200 C and (-) 370C. The
solution contained 1.7 wt% of HA-Tyr and 20 pL/mL of liposomes. Liposomes were synthesized
with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication,
-20 0 C freezing, and rehydration volume ratio = 0.1, and were washed with 0.1 M of CaC12.
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For various clinical needs, gelation times (at both 200 C and 370C) could be modulated by
parameters such as the liposome loading, the HRP concentration in the liposomes, and the HA-
Tyr concentration. As the liposome loading increased, gelation time was reduced at both 200 C
and 370 C (Figure 2.12). Likewise, as the HRP loading within the liposomes increased, gelation
time was also decreased (Figure 2.13). In both cases, the HRP added was increased, thereby
reducing the gelation time. In a similar manner, the gel point could be further tuned by adjusting
the parameters described in Section 2.3.1 to control the total HRP released from the liposomes.
The gelation time could also be adjusted by the concentration of HA-Tyr to vary the Tyr or
crosslinking groups in the solution. Figure 2.14 shows that the gelation time decreased as HA-
Tyr concentration increased.
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Figure 2.12. Effect of the liposome concentration on the gelation time at (o) 20 0 C and (+) 370 C.
The solution contained 1.7 wt% of HA-Tyr. Liposomes were synthesized with 60 mg/mL of lipid
(DPPC:DMPC weight ratio - 2.3), 2 mg/mL of HRP, 30-min sonication, -200 C freezing, and
rehydration volume ratio = 0.1, and were washed with 0.1 M of CaC12.
1000
800
600
400
200
0
0.0 0.5 1.0 1.5 2.0
HRP Loading (mg/mL)
Figure 2.13. Effect of the HRP loading within liposomes on the gelation time at (A) 20'C and (*)
370 C. The solution contained 1.7 wt% of HA-Tyr and 50 gL/mL of liposomes. Liposomes were
synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 30-min sonication, -20 0 C
freezing, and rehydration volume ratio = 0.1, and were washed with 0.1 M of CaC12.
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Figure 2.14. Effect of the HA-Tyr concentration on the gelation time at (0) 200 C and (*) 370 C.
The solution contained 50 pL/mL of liposomes. Liposomes were synthesized with 60 mg/mL of
lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication, -20'C freezing,
and rehydration volume ratio = 0.1, and were washed with 0.1 M of CaC12.
In order to maximize the gelation time at room temperature without compromising the
gelation time at 370 C, it was important to select an appropriate solution for rinsing off the
liposomes after rehydration. HRP, a natural protein that resides on the cell membrane [32], tends
to adhere to liposome membranes [33], and insufficient deactivation of the unencapsulated HRP
on the outer liposome membrane would cause prematured gelation at room temperature. Figure
2.15. 2.15 shows that this deactivation was dependent on the composition of the wash solution
used. PBS and H20 solutions did little to deactivate HRP, resulting in rapid gelation at room
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temperature. NaCl gave rise to a small amount of deactivation, but the increase in ionic strength
might have helped to control the osmotic stresses and prevent HRP leakage, thereby prolonging
the gelation time at 20 0 C. The divalent cations, in particular Ca2+, led to significant HRP
deactivation, resulting in slow gelation at room temperature without a significant increase of
gelation time at 370 C. Previous studies have shown that high Ca 2+ concentration reduces
peroxidase activity, and can destabilize and change the native conformation of peroxidases [34,
35]. Gelation time at 370 C was not significantly changed by the wash solutions because the HRP
within the liposomes was not affected by the exterior cations, since small, charged ions have low
permeability through the lipid membranes [36].
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Figure 2.15. Effect of the liposome wash solution on the gel point of HA-Tyr/H20 2/HRP
liposome mixture at (i) 200C and (a) 37 0 C, and (A) the HRP deactivation in the respective
solutions. The solution contained 1.7 wt% of HA-Tyr and 50 IL/mL of liposomes. Liposomes
were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP,
30-min sonication, -200 C freezing, and rehydration volume ratio = 0.1.
While CaCl2 was found to best deactivate surface HRP, the gel point was found to be
very sensitive to the CaCl2 concentration of the wash solution. Figure 2.16 shows that the gel
point at 20 0 C was maximized at a CaC12 concentration of - 0.1 M. Higher salt concentration
would likely result in a hyperosmotic environment, with a flux of water carrying HRP out of the
liposomes. The size of liposomes, incubated at various concentrations of CaCl 2, is shown in
Figure 2.17. The liposome size decreased at CaCl2 concentrations above 0.1 M, indicating
liposome shrinkage due to HRP flow out of liposome's aqueous core. This release of HRP then
caused prematured gelation at room temperature.
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Figure 2.16. Effect of the CaCl2 concentration on the gelation time at (+) 20'C and (n) 370 C. The
solution contained 1.7 wt% of HA-Tyr and 50 jgL/mL of liposomes. Liposomes were synthesized
with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication,
-200 C freezing, and rehydration volume ratio = 0.1.
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Figure 2.17. Effect of the CaCl2 concentration on the liposome size. Liposomes were synthesized
with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication,
-20 0 C freezing, and rehydration volume ratio = 0.1.
The benefit of the HRP liposome system is illustrated in Figure 2.18. As discussed in the
Introduction, the working time and mechanical strength of polymer-crosslinker systems are
generally modulated by adjusting the crosslinker concentration. For the HA-Tyr system, the
working time was gauged by the gel point, while the mechanical strength was characterized by
the storage modulus, G'. G' and gel point of the HA-Tyr/H20 2/HRP solution were obtained at
various HRP concentrations, and an inverse relationship was found for G' and gel point (Figure
2.18). Thus, there was a trade-off between the working time and mechanical strength for the
system derived with HA-Tyr/H20 2/HRP solution. However, by utilizing thermally triggered
* .
liposomes to encapsulate HRP, the working time could be prolonged without greatly sacrificing
the mechanical strength. Figure 2.18 also illustrates an inverse relationship between G' and gel
point for the HA-Tyr/H20 2/HRP liposomes. However, the gel point for the HA-Tyr/H20 2/HRP
liposomes was on the order of hours, which was considered well above the required working time
(typically on the order of minutes) for injectable materials [37, 38]. To further illustrate, in order to
obtain a stiff scaffold with G' of 3000 Pa, clinicians would have less than 30 sec to prepare and inject
a HA-Tyr/H202/HRP solution. In contrast, the use of HA-Tyr/H20 2/HRP liposomes would allow for
a working time of > 1 h, while maintaining a curing time in the defect site of 2 min.
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Figure 2.18. Storage modulus vs. the gelation time at 200 C for (m) HA-Tyr/H20 2/HRP solution
and (o) HA-Tyr/H20 2/HRP liposomes. HA-Tyr concentration was 1.7 wt% in PBS. Liposomes
were synthesized with 60 mg/mL of lipid (DPPC:DMPC weight ratio = 2.3), 30-min
sonication, -20 0C freezing, and rehydration volume ratio = 0.1. The HRP concentration in the
precursor solution was varied from 0.1 to 2 mg/mL. Liposomes were added at a concentration of
50 tL/mL of HA-Tyr solution. Note: the arrow refers to a gel point longer than 720 min.
2.3.3 Injectability Study In Vivo
In vivo studies were conducted by injecting HA-Tyr/H20 2/HRP liposomes
subcutaneously in a mouse model. The solution remained a liquid at room temperature, and was
injected without difficulty through a syringe. Based on palpitation, the solution cured within 7
min of exposure to body temperature, and an intact gel was harvested upon sacrifice of the
mouse (Figure 2.19). This study illustrated that there was no interfering reaction in vivo that
inhibited the enzyme release or crosslinking reaction.
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Figure 2.19. Intact gel harvested 2 h after injection. The solution contained 1.7 wt% of HA-Tyr
and 20 pgL/mL of liposomes. Liposomes were synthesized with 60 mg/mL of lipid (DPPC:DMPC
weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication, and rehydration volume ratio = 0.1.
2.4 Summary
A thermally triggered injectable HA scaffold was created by encapsulating a crosslinking
agent, HRP, in thermoresponsive liposomes, which were then suspended in an HA-Tyr solution.
At room temperature, HRP was enclosed within the liposomes and prevented from reacting with
the polymer. This allowed the system to remain as a liquid and be injected through a syringe.
Upon introduction into the defect site and exposure to body temperature, the permeability of the
lipid membrane was significantly enhanced, releasing the HRP for reaction with HA-Tyr to form
a hydrogel scaffold.
The uniqueness of the system lies in the development of an injectable tissue engineering
scaffold through the encapsulation of a crosslinking agent, in particular a protein, within
liposomes that have traditionally been employed for drug and gene delivery. Since liposomes are
versatile carriers, this platform can potentially be extended to impart temperature sensitivity and
injectability to a variety of crosslinking agent-polymer systems, such as at-transglutaminase-
collagen, or active catalyst-monomer systems, such as thrombin-fibrin.
The premise that HRP would be released and result in gelation was supported by release
studies and gelation kinetic studies. It was shown that the liposomes successfully encapsulated
HRP at 250 C. HRP was rapidly released into the environment at 370C. When the liposomes were
suspended in a HA-Tyr solution, rheometry showed that the liposome/polymer solution remained
a liquid at room temperature for extended periods, while curing and forming a hydrogel network
rapidly at body temperature.
It was critical to optimize the encapsulation of HRP within the liposomes, while retaining
the enzymatic activity. The dehydration-rehydration vesicle synthesis was selected so as to avoid
exposure of the enzyme to high temperatures and organic solvents that could potentially damage
the peroxidase activity. Parameters influencing liposome fusion during freezing and
lyophilization were found to be very important as enhanced liposome fusion would promote
HRP encapsulation. Increased lipid concentration and sonication time were shown to increase
HRP encapsulation, while increased cholesterol concentration and freezing rate decreased HRP
encapsulation. The optimal HRP concentration of the precursor solution added to the blank
liposomes was 2 mg/mL. As the amount of HRP added increased, encapsulation increased, but
excess HRP would result in liposome destabilization/leakage and reduced HRP encapsulation.
The optimal rehydration volume ratio was 0.1, which balanced the need to incubate the re-
formed liposomes prior to washing and the excessive dilution of HRP during re-formation.
The gelation times at 20 0 C and 370 C were controlled by varying parameters, such as the
concentration of HRP loaded within the liposomes, the concentration of HRP-loaded liposomes,
and the HA-Tyr concentration. By increasing the first two parameters, the concentration of HRP
added was effectively increased, decreasing the gelation time. By increasing the HA-Tyr
concentration, the crosslinking group was increased, reducing the gelation time.
The most important parameter in managing the gelation time at room temperature was
found to be the solution used to wash the liposomes. Since proteins tended to adhere to liposome
surface, deactivation of HRP on the exterior of liposomes was crucial in preventing prematured
gelation at room temperature. Divalent cations, particularly Ca 2+, were shown to be effective in
deactivating HRP on the surface. However, excess Ca2+ concentration would cause osmotic
stresses, resulting in HRP leakage and rapid gelation at room temperature. The optimal Ca 2+
concentration was found to be - 0.1 M.
With an understanding of the optimization of HRP encapsulation and modulation of
gelation times, we could design injectable scaffolds with specific gelation kinetics and
mechanical properties. For example, to attain a scaffold with a working time of > 2 h and a G' of
> 1000 Pa, liposomes were synthesized with a high HRP content (e.g. 0% cholesterol, 60 mg/mL
of lipid, 2 mg/mL of HRP), 30-min sonication, -200 C freezing, and 0.1 rehydration volume ratio,
and added at a concentration of 30 pL/mL to the HA-Tyr solution. Both working time and G'
could be easily tuned by adjusting the HRP loaded within the liposomes, the liposomes added to
the solution, and the HA-Tyr concentration. The next chapter describes the application of the
HA-Tyr system to cartilage regeneration in vivo, and the various factors that affect the rate and
quality of tissue synthesis.
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Chapter 3 - Cartilage Synthesis in Hyaluronic Acid-Tyramine Constructs
3.1 Introduction
3.1.1 Cartilage
Articular cartilage is a tissue that serves as a shock absorber and lubricant in the joint
environment. It is characterized by its low-friction surface and ability to withstand compression,
which act together to provide stable movement. These properties are attributed to the unique
composition of the tissue. The extracellular matrix (ECM) mainly consists of water (- 85% of
the total weight), collagen (67-86% of the dry weight), and proteoglycans (15-25% of the dry
weight) [1, 2]. The collagen fibrils, 95% of which are Type II collagen, form a mesh-like
network, through which the proteoglycans are interspersed. The negatively charged
glycosaminoglycans (GAGs), including hyaluronic acid (HA), chondroitin sulfate, dermatan
sulfate, keratan sulfate, and heparan sulfate, are highly hydrophilic and tend to repel each other
while simultaneously complexing with the positively charged collagen fibers. The high water
content and strong network lead to the high compressibility and flexibility unique to cartilage [3].
3.1.2 Cartilage Tissue Engineering Scaffolds
When damaged, cartilage has limited reparative ability largely due to the fact that it has a
low cell concentration and very little vasculature [4]. It lacks the number of cells to synthesize a
sufficient amount of new tissue, and the blood to deliver cells and signaling molecules that
promote healing to the defect site. In recent years, tissue engineering has been proposed as a
means to introduce these cells and signaling molecules into the defect site in order to enhance the
tissue's natural regenerative ability.
As discussed in the Introduction, the scaffold is one of the most important aspects of
tissue engineering and must possess several key features: (1) be non-toxic and non-inflammatory,
(2) promote cell stability and matrix synthesis, (3) possess interconnecting pores that allow cell
migration and tissue growth, (4) be bioresorbable, degrading either during or after healing, (5) be
mechanically robust, and (6) be capable of being fabricated to fit the shape of defect sites [5, 6].
Various synthetic and natural scaffold materials have been studied to meet these criteria
for cartilage regeneration. Synthetic materials are often chosen because the chemical
composition can be tailored for specific chemical and mechanical properties, and because they
can be mass produced. Poly(lactic acid), poly (glycolic acid) and their copolymers have been
widely studied as they are biodegradable and FDA approved for use in therapeutic devices [7, 8].
Chondrocytes seeded on these scaffolds have demonstrated cell attachment and proteoglycan
synthesis [9, 10]. The disadvantages of these scaffolds lie in their brittleness. Implantation of
these materials also require surgery, and the acidic by-products of degradation have been
reported to cause local cell necrosis [3, 11, 12]. Alternatively, poly(ethylene glycol) (PEG)
derivatives have been investigated as they are relatively inert, and can be modified to be
injectable. These scaffolds have been shown to enable cell stability, and facilitate the production
of a cartilaginous matrix when implanted in vivo [5, 10]. However, as PEG is not naturally
biodegradable, the scaffold would never be completely replaced by regenerated tissue.
Natural polymers, on the other hand, have been studied due to their favorable
cytocompatibility and bioactivity [9]. Perhaps the most widely used for cartilage regeneration
has been collagen, of which cartilage is largely composed. Collagen, in particular Type II
collagen, has shown the ability to maintain the chondrocyte phenotype and promote matrix
production [5, 13, 14, 15]. The concern with the use of collagen lies in the possibility of an
immune response and transfer of pathogens as collagen is generally derived from xenogenic
sources [3, 6]. Alginate and agarose are derivatives of algae and kelp, respectively, and are also
commonly chosen materials, as they have demonstrated good biocompatibility. Both are linear
polysaccharides that have been shown to support the chondrocyte phenotype, and to demonstrate
the production of cartilage-specific markers [5]. The limitation of these materials is that both are
non-biodegradable in mammals because they are derived from plant sources, and would remain
in the defect site indefinitely.
Like collagen, HA is one of the main components of cartilage and was chosen in this
study because it is biocompatible, biodegradable and non-immunogenic. Furthermore, its
presence has been shown to be important in cartilage function, as the blockage of the CD44
receptor for HA in chondrocytes has been found to induce degradation of the cartilage matrix [16,
17]. However, HA cannot be used as a scaffold in its native form because it is a liquid in solution
that cannot form a three-dimensional (3D) structure without modification. Various methods have
been explored to achieve HA crosslinking, such as those involving carbodiimides, divinyl
sulfones, polyvalent hydrazides, and esterification [18, 19, 20]. However, these reactions require
relatively toxic reagents, limiting the ability of scaffold formation in the presence of cells or in
situ. In order to enable HA crosslinking to occur under mild conditions, Kurisawa et al.
developed the HA-tyramine (HA-Tyr) system, in which tyramine groups are conjugated onto the
HA backbone [21]. In the presence of H20 2 and horseradish peroxidase (HRP), the tyramine
groups would react with each other to form a hydrogel scaffold. Because Tyr, peroxidases and
H20 2 are all natural components of the human body, crosslinking and scaffold formation occur
with minimal toxicity. Furthermore, the resulting hydrogel, of which over 98% is water, forms a
highly porous network and, as described in Chapter 2, can be made to be injectable, enabling the
scaffold to fill the shape of the defect through a minimally invasive procedure.
In this study, chondrocytes were encapsulated within HA-Tyr hydrogels to investigate the
potential of the HA-Tyr system as a scaffold for cartilage tissue engineering. As shown in Figure
3.1, cartilage cells, harvested from porcine joints, were suspended in an HA-Tyr/H20 2 solution,
to which HRP was added to form a hydrogel around the cells. The cell-seeded constructs were
then implanted subcutaneously into a mouse model, and harvested at 2, 4 and 8 weeks. As GAG
and collagen represent the major dry components of natural cartilage [22], the constructs were
evaluated biochemically for GAG content and by histomorphometry for collagen content.
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Figure 3.1. Cells were suspended within the HA-Tyr/H20 2 solution to form hydrogel disks upon
HRP addition. The hydrogel disks were then implanted subcutaneously into a mouse model.
3.2 Experimental
3.2.1 Chondrocyte Isolation
Chondrocytes were isolated from the articular cartilage of the femur, patella and tibia of
porcine legs (5-6 months old) that were obtained from the local abattoir. The tissue was cut into
small pieces (1 mm3) and digested in a 0.2 wt% Type 2 collagenase solution (in F-12 medium
supplemented with 0.1 M of non-essential amino acids, 0.5 jtg/mL of fungizone, 1 wt% of
penicillin-streptomycin, and 0.4 mM of L-proline) at 370C for 12 h. The cell solution was then
filtered through a 100-ipm strainer and centrifuged (8000g, 10 min) twice with PBS. The
collagenase was purchased from Worthington Biochemical. The F-12 medium, non-essential
amino acids and fungizone were purchased from Invitrogen. The penicillin-streptomycin and L-
proline were purchased from Sigma-Aldrich.
3.2.2 Toxicity Study
Chondrocytes were seeded in a 96-well plate at 1000 cells/well (n = 5), and maintained at
370 C and 5% of CO 2 in F-12 medium supplemented with 10% of fetal bovine serum (FBS), 0.1
M of non-essential amino acids, 0.5 [pg/mL of fungizone, 1 wt% of penicillin-streptomycin, and
0.4 mM of L-proline, which will herein be referred to as "complete medium". HA-Tyr hydrogels
(400 pL) prepared with various HA-Tyr, HRP or HRP liposome, and H20 2 concentrations were
aseptically synthesized, and incubated with 5 mL of complete F-12 medium. HA-Tyr was
synthesized as described by Kurisawa et al. with 132 kDa HA and 7-8% substitution of tyramine
[21]. Liposomes were synthesized as described in Chapter 2 with 60 mg/mL of lipid
(DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30-min sonication, -20 0 C freezing, and
rehydration volume ratio = 0.1, and were washed with 0.1 M of CaCl 2. At each time point,
medium was removed from the respective hydrogel tubes, and used to replenish the medium for
the chondrocytes. Cell viability was measured with the MTT assay for mitochondrial activity.
The MTT assay kit was purchased from ATCC.
3.2.3 Subcutaneous Implantation of HA-Tyr Constructs
Chondrocytes were suspended in a sterile-filtered HA-Tyr (dissolved in complete
medium) and H20 2 (5 wt%, 5 pL per 25 mg of HA-Tyr) solution. 50 ptL of the HA-
Tyr/H202/chondrocyte solution were combined with 5 jtL of HRP (0.125 mg/mL), and placed in
a mold to create a cylindrical gel with a diameter of 8 mm and a thickness of - 1 mm. The gels
(n = 6) were then implanted subcutaneously in the dorsum of SCID mice, which were sacrificed
at weeks 2, 4 and 8. Chondrocytes used for implantation were encapsulated immediately post-
harvest, and each experiment, i.e. each graph shown, was conducted with one set of
chondrocytes harvested from an individual pig.
3.2.4 Histology
Harvested constructs were fixed in formalin for at least 24 h. The constructs (n = 2) were
then paraffin-embedded and stained with Safranin O and Masson's Trichrome. Masson's
Trichrome was purchased from Richard-Allan Scientific. Safranin O and Fast Green were
purchased from Alfa Aesar.
Histomorphometry was performed on sections stained with Masson's Trichrome to
quantify collagen content. Digital images were acquired at the same brightness and exposure
time on an Olympus DP71 camera mounted on an Olympus BX51 microscope. Images were then
split into red, green and blue (RGB) planes on Image J software, and the data were loaded onto
Matlab. To measure the blue intensity of the sections, a method similar to that developed by
Martin et al. was employed [23]. For each pixel, the blue fraction, BF, was defined as BF =
B/(R+G+B). BF was then normalized to BF,N, where BF,N was set to 0 if BF < 0.38 and if R/G <
0.98. This eliminated pixels that were either not stained blue or were stained purple (the nuclei).
1 0.38
All other pixels were proportionally scaled from 0 to 1, i.e. BF,N =- BF- . The
1-0.38 1-0.38
blue content for each pixel was then calculated as Bc = BF*BF,N, and the blue content of the
image (Bc) was calculated as the average of all pixels in the image. Results were reported as a
percentage of the blue content of natural porcine articular cartilage stained at the same time, so
as to account for variations in staining procedure and reagents. Three sections of each sample
were stained, and four to five images were taken of each section. Images shown represent the
average.
Immunohistochemistry was performed by deparaffinizing and rehydrating tissue sections.
The sections were then enzymatically treated with hyaluronidase (2%) for 30 min and trypsin
(4%) for 30 min at room temperature. Non-specific binding was then blocked by incubating
sections with horse serum (5%) for 1 h at room temperature. The primary antibody (monoclonal
mouse anti-Type II collagen) was then added at a concentration of 10 Pg/mL overnight. After
incubating with the secondary antibody (goat anti-mouse IgG-FITC) at 20 Pg/mL for 1 h at room
temperature and then 4',6-diamidino-2-phenylindole (DAPI) for 10 min, the slides were mounted.
Porcine articular cartilage was used as a positive control, and porcine fibrocartilage, which
mainly consisted of Type I collagen, was used as a negative control. Hyaluronidase and trypsin
were purchased from Sigma-Aldrich. Horse serum, the secondary antibody and DAPI were
obtained from Invitrogen. The primary antibody was purchased from Chondrex.
3.2.5 GAG Quantification
Harvested constructs (n = 4) were sonicated with a probe-tip sonicator for 40-60 sec, and
then digested in papain (0.125 mg/mL in 100 mM of phosphate buffered saline (PBS) solution,
10 mM of ethylenediaminetetraacetic acid (EDTA) and 10 mM of cysteine) at 600 C for 15 h.
Digested constructs were filtered through a 0.45-tm syringe filter, and the GAG concentration
was calorimetrically determined by the Blyscan dimethylmethylene blue assay. Papain was
purchased from Worthington, PBS was purchased from EMD Biosciences, EDTA and cysteine
were purchased from Sigma, and the Blyscan reagents were purchased from Biocolor.
3.2.6 Statistics
Graphs of GAG and blue content were depicted as mean ± standard deviation. Two-factor
analysis of variance (ANOVA) was conducted to determine whether significance existed at p <
0.05. Tukey post hoc analysis was also performed to determine whether there was significance at
p < 0.05 between experimental groups. Calculations were conducted on Matlab.
3.2.7 Degradation Study
Hydrogels were synthesized by mixing 1 mL of HA-Tyr and collagen at various
concentrations, with H20 2 (5 wt%, 5 gtL per 25 mg of HA-Tyr) and 100 ptL of HRP (0.125
mg/mL). The mixture was quickly pipetted between two glass plates, which were separated by a
0.75-mm spacer, and allowed to set for 1 h. Hydrogel disks (1 cm-diameter) were cut out with a
punch, and placed in complete medium to swell overnight. The hydrogels were then placed in a
hyaluronidase solution (125 Units/mL in complete medium), and the wet weight was measured
over time. Bovine testicular hyaluronidase was purchased from Sigma.
3.2.8 Incorporation of Collagen
Type II collagen (5 ptg/mL in 0.1 M of acetic acid) was incorporated into the hydrogels
by mixing the collagen solution with an HA-Tyr solution (0.5 wt% in PBS), and incubating the
mixture overnight at room temperature. H20 2 (5 wt%, 5 lpL per 25 mg of HA-Tyr) and HRP
(0.125 mg/mL) were then added. The resulting hydrogel's stiffness, measured by the storage
modulus, G', was evaluated by oscillatory rheometry at 370C on a ThermoHaake Rheoscope 1
with a 25-mm, 10 titanium cone at 1% strain at a frequency of 1.0 Hz. Bovine Type II collagen
was purchased from AbD Serotec.
Chondrocytes were encapsulated as described in Section 3.2.3. The constructs were
composed of HA-Tyr (0.5 wt%), sterile-filtered Type II collagen, H20 2 (5 wt%, 5 PL per 25 mg
of HA-Tyr), HRP (0.125 mg/mL), and 50x106 cells/mL. HA-Tyr/collagen/H 202/HRP/
chondrocyte constructs were implanted subcutaneously in mice.
3.2.9 Comparison with Other Scaffolds
Chondrocytes were suspended in steam-sterilized low melting point agarose (2 wt%).
Agarose was heated until it became a liquid, and was allowed to cool to - 370 C, upon which
cells were added to achieve a concentration of 50x 106 cells/mL. The solution was pipetted into
cylindrical molds (50 gpL, 8 mm in diameter, - 1 mm in thickness), and solidification occurred as
the mixture further cooled to room temperature. Agarose was purchased from Invitrogen.
Alginate/chondrocyte constructs were created by combining steam-sterilized alginate (1.5
wt%) with a cell suspension to arrive at a final cellularity of 50x 106 cells/mL. The mixture was
then added drop-wise (50 pL) to a sterile-filtered CaC12 solution (0.1 M) to form hydrogel beads.
Alginate was purchased from Sigma.
Chondrocytes in solution were injected through a 21-gauge needle into the mid-line of
pre-cut Helistat® sponges (50 pL, 3 mm x 6 mm x 5 mm sponges) to achieve a final cell
concentration of - 50x 106 cells/mL. Helistat® sponges were purchased from Integra LifeSciences.
All constructs were implanted subcutaneously in SCID mice as described in Section 3.2.3.
3.2.10 Incorporation of Liposomes
Liposomes were aseptically synthesized as described in Section 3.2.2. The HRP release at
37C was measured to be 90 Units/mL of liposome. HRP-encapsulated liposomes were
combined at 30 pL/mL with a solution of HA-Tyr (0.5 wt%), Type II collagen (0.05 wt%), H20 2
(5 wt%, 3 ipL/mL) and chondrocytes (50x106 cells/mL). The mixture was added drop-wise (50
VL) onto a temperature-controlled plate (Leica HI 1220) set at 370 C to form hydrogel disk
constructs. HRP activity was assessed by the Amplex Red Assay for peroxidase activity.
In order to compare with the above, 50 ptL of a solution of HA-Tyr (0.5 wt%), Type II
collagen (0.05 wt%), H20 2 (5 wt%, 3 pL/mL) and chondrocytes (50x106 cells/mL) were
combined with 5 VL of HRP (30 Units/mL). As an additional comparison, constructs were
synthesized by combining 50 jtL of a solution of HA-Tyr (0.5 wt%), Type II collagen (0.05
wt%), H20 2 (5 wt%, 3 L/mL), chondrocytes (50x 106 cells/mL), and a blank liposome (30
ptL/mL) solution with 5 jiL of HRP (30 Units/mL). Blank liposomes were synthesized in the
same manner as the HRP-encapsulated liposomes, except that water instead of HRP solution was
added prior to freeze drying.
3.2.11 Injection Studies
Liposomes, as described in Section 3.2.10, were combined at 30 jiL/mL (90 Units/mL of
liposome) with a solution of HA-Tyr (0.5 wt%), Type II collagen (0.05 wt%), H20 2 (5 wt%, 4
[tL/mL) and chondrocytes (50x 106 cells/mL). The precursor solution (100 tL, n = 6) was then
injected subcutaneously in SCID mice.
3.3 Results and Discussion
3.3.1 Toxicity Studies
In order to evaluate the safety of the HA-Tyr system for application to cartilage
regeneration, the materials were first tested for cytotoxicity in vitro. Hydrogels were incubated in
complete medium, which was subsequently used to culture chondrocytes seeded on a plate. The
cell number at each time point was measured, and compared to that of cells cultured in medium
without HA-Tyr hydrogels. Figures 3.2-3.4 show that within the hydrogel concentration ranges
examined, the presence of HA-Tyr, H202 and HRP within the hydrogels had little effect on cell
viability and growth over 7 days, and were therefore non-cytotoxic. Figure 3.5 shows the effect
of hydrogels that were formed by the thermally triggered release of HRP from HRP-encapsulated
liposomes. It was found that the use of HRP liposomes as well as the further addition of blank
liposomes did not affect cell viability, demonstrating that neither the means of HRP delivery nor
the presence of DPPC and DMPC in the form of liposomes resulted in toxicity.
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Fig 3.2. Cell viability of culture (m) with untreated medium,
hydrogels composed of 0.5 [tM of H20 2, 10 tg/mL of HRP,
(m) 3.3 wt% of HA-Tyr.
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Fig 3.4. Cell viability of culture (m) with untreated medium, and with medium conditioned with
hydrogels composed of 1.7 wt% of HA-Tyr, 0.5 pM of H20 2, and (a) 10 pg/mL, (m) 23 jtg/mL,
(m) 45 [tg/mL, (m) 90 Vg/mL and (m) 180 pg/mL of HRP.
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Figure 3.5. Cell viability of culture (m) with untreated medium, and with medium conditioned
with hydrogels composed of 1.7 wt% of HA-Tyr, 0.5 VM of H20 2 , and (m) 30 jiL/mL of HRP
liposomes, (m) 30 jpL/mL of HRP liposomes + 10 VL/mL of blank liposomes, (m) 30 PL/mL of
HRP liposomes + 20 [tL/mL of blank liposomes and (a) 30 [tL/mL of HRP liposomes + 30
VL/mL of blank liposomes.
3.3.2 Implantation of Cell-Seeded Scaffolds
Chondrocytes isolated from porcine joints were encapsulated within HA-Tyr hydrogel
scaffolds, and implanted subcutaneously in SCID mice. As illustrated in Figure 3.6, natural
chondrocytes have an ovoid to round shape with small, acentric nuclei. They are responsible for
secreting the ECM, and are immobilized in isogenous groups of 2-4 cells, which arise from the
mitosis of a single cell. Chondrocytes encapsulated in the HA-Tyr scaffolds displayed similar
morphologies as well as isogenous groups, demonstrating that this system promoted chondrocyte
stability and proliferation.
The cartilage matrix is mainly composed of GAG and collagen, and appears amorphous
and smooth with an invisible network of collagen fibers [24]. Because of the high concentrations
of acidic sulfhydryl and carboxyl groups, the matrix is basophilic, particularly in the territorial
matrices immediately around the cells, which stain more richly in basic dyes such as Safranin O
[25, 26, 27, 28]. Figure 3.6 shows that significant GAG and collagen were produced within HA-
Tyr/H20 2/HRP/chondrocyte constructs over 8 weeks, and that, of the collagen, the majority
appeared to be composed of Type II collagen, one of the defining characteristics of articular
cartilage. Furthermore, the dense matrix synthesized resembled that of natural cartilage, with a
ground glass appearance and more intense staining for Safranin O immediately adjacent to the
cells. The GAG content of natural porcine articular cartilage was measured to be - 3% of the wet
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weight, while that produced in the HA-Tyr/chondrocyte constructs was found to be - 1.2 wt%
after 8 weeks; the collagen content, based on histomorphometry, reached - 40% that of natural
cartilage over 8 weeks. Observing constructs over longer periods would likely show further GAG
and collagen production, approaching the natural composition. This difference might have also
been due to the fact that the HA-Tyr constructs were implanted ectopically. Constructs implanted
in the joint would be exposed to the joint fluid and mechanical forces important to cartilage
development, and therefore produce matrix components further resembling natural cartilage.
As a point of comparison, HA-Tyr scaffolds that did not contain any cells were also
implanted in vivo, and they showed no sign of cells or matrix deposition, as verified by GAG
quantification and histology (Figure 3.6). Therefore, the GAG and collagen produced were
attributed to the presence of chondrocytes within the scaffolds.
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(b)
(c)
Figure 3.6. (i) Natural articular cartilage, (ii) HA-Tyr/H20 2/HRP/chondrocyte constructs (U.)
wt% HA-Tyr, 50x 106 cells/mL), and (iii) HA-Tyr/H20 2/HRP constructs (0.5 wt% HA-Tyr) at
Week 8 stained by (a) Safranin O for GAG and (b) Masson's Trichrome for collagen, and (c)
immunostained for Type II collagen.
3.3.3 Effect of Crosslink Density and Degradation Rate
For tissue engineering scaffolds, the degradation rate is an important consideration.
Based on the idea of isomorphous replacement, the scaffold degradation rate should match the
tissue synthesis rate [5, 29, 30]. Therefore, in optimizing the HA-Tyr system for cartilage
production, various degradation rates were examined. HA mainly degraded via cleavage of the
glycosidic bonds by hyaluronidase, which was produced by chondrocytes as a means of tissue
remodeling [31, 32]. In order to vary the degradation rate, the hydrogels were crosslinked to
different degrees by adjusting the HA-Tyr concentration. As the HA-Tyr concentration increased,
the number of tyramine groups and crosslink points was effectively increased, and the
degradation rate of the scaffold decreased (see Figure 3.7).
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Figure 3.7. Degradation of HA-Tyr/H20 2/HRP hydrogel with (o) 0.5 wt%, (A) 0.8 wt%, (in) 1.3
wt% and (*) 1.7 wt% of HA-Tyr in hyaluronidase solution.
The effect of the degradation rate in vivo was then studied by implanting subcutaneously
HA-Tyr/H20 2/HRP/chondrocyte scaffolds at various HA-Tyr concentrations. In order to control
the response of the cells to the presence of HA, 64 kDa HA was added to maintain a constant HA
concentration, creating a semi-interpenetrating network. Low molecular weight HA was chosen
to enable rapid diffusion of HA out of the scaffold pores, facilitating rapid degradation at low
HA-Tyr concentrations. Figure 3.8 shows that as HA-Tyr concentration decreased and
degradation rate increased, GAG production within the constructs increased. At lower HA-Tyr
concentrations, histological sections in Figures 3.9 also showed larger areas of collagen secreted
by cells and greater collagen content, measured by the overall blue content. The trend could be
explained as follows: (1) rapid degradation created more space for the cells to synthesize matrix
components, (2) lower crosslink densities enhanced diffusion of nutrients and oxygen, (3) lower
crosslink densities, and therefore softer materials, allowed chondrocytes within the scaffold to
contract, resulting in dynamic pore reduction (DPR) during which the intercellular space
decreased and the effective cell density increased, promoting chondrogenesis [33], and (4) rapid
degradation produced higher concentrations of low molecular weight HA, which have been
known to induce cytokine activity and stimulate ECM turnover [18].
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Figure 3.8. GAG production within HA-Tyr/H 20 2/HRP/chondrocyte constructs with (o) 0.5 wt%,(A) 0.8 wt%, (m) 1.3 wt% and (+) 1.67 wt% of HA-Tyr, and 50x 106 cells/mL.
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Figure 3.9. (a-d) Masson's Trichrome staining for collagen and (e) quantification of blue content
within HA-Tyr/H20 2/HRP/chondrocyte constructs with (a, *) 0.5 wt%, (b, N) 0.8 wt%, (c, A) 1.3
wt% and (d, o) 1.7 wt% of HA-Tyr, and 50x 106 cells/mL.
3.3.4 Effect of Collagen Incorporation
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Though rapid degradation was shown to be favorable for cartilage generation, the
scaffold should also not be too soft, as cartilage is a structural tissue and must be able to
withstand the physiological stresses within the joint. Therefore, it was proposed that Type II
collagen, which is rapidly resorbed in vivo, be incorporated into the scaffold to increase its
mechanical strength without decreasing degradation rate. The anionic HA can form a polyionic
complex with cationic collagen, and in natural cartilage, this interaction provides mechanical
strength to the tissue [34]. Figure 3.10 shows that incorporating small amounts of collagen into
the HA-Tyr hydrogels increased the scaffold mechanical stiffness, measured by G'. The
maximum G' was achieved with 0.05 wt% of collagen, whose value was more than double of
that without collagen. Further addition of collagen, however, resulted in phase separation and
eventual precipitation of the complex, and therefore lower mechanical strength.
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Figure 3.10. Effect of collagen incorporation on the G' of HA-Tyr/collagen/H 202/HRP hydrogels
with 0.5 wt% of HA-Tyr.
Despite increasing the mechanical strength, Figure 3.11 shows that 0.05 wt% and 0.10
wt% of collagen did not significantly affect the degradation rate of the hydrogels in
hyaluronidase solution. This suggested that low concentrations of collagen did not inhibit the
diffusion of hyaluronidase into the hydrogel or block the hyaluronidase binding sites on the HA
chain.
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Figure 3.11. Degradation of HA-Tyr/H20 2/HRP hydrogels with 0.5 wt% of HA-Tyr and (+) 0
wt%, (o) 0.05 wt% and (A) 0.10 wt% of Type II collagen in hyaluronidase.
HA-Tyr/collagen/H 20 2/HRP/chondrocyte constructs were implanted in vivo to study the
effect of collagen on cartilage regeneration. Type II collagen is one of the major components of
cartilage, and chondrocytes are known to have a cell surface protein, Annexin V, that binds Type
II collagen and anchors the cell onto the ECM [35]. Type II collagen has also been shown to
stabilize the chondrocyte morphology, as well as improve GAG and protein production within
cartilage scaffolds [14, 15]. Figure 3.12 shows that a collagen concentration of 0.05 wt% within
the hydrogels enhanced GAG production over that without collagen at Weeks 2 and 4, but that
the two experimental groups had become almost similar by Week 8. Figure 3.13, on the other
hand, shows a more delayed effect, where statistically greater collagen production within the
0.05 wt% constructs was not observed until Weeks 4 and 8. Type II collagen was insoluble in
water and was dissolved in dilute acetic acid, and collagen concentrations of > 0.10 wt% resulted
in an overall acetic acid concentrations of > 20 mM within the hydrogel. Figures 3.12-3.13
suggest that these concentrations of acetic acid inhibited both GAG and collagen production. The
histological sections clearly showed that the majority of cells within constructs with 0.24 wt% of
collagen had died. The cells appeared almost as shadows, and did not take up the hematoxylin
dye, which would normally stain for nuclei.
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Figure 3.12. GAG production within HA-Tyr/collagen/H 20 2/HRP/chondrocyte constructs with
0.5 wt% of HA-Tyr, 50x106 cells/mL, and (+) 0 wt%, (s) 0.05 wt%, (A) 0.10 wt% and (x) 0.24
wt% of Type II collagen.
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Figure 3.13. (a-d) Masson's Trichrome staining for collagen and (e) quantification of blue
content within HA-Tyr/collagen/H 20 2/HRP/chondrocyte constructs with 0.5 wt% of HA-Tyr,
50x106 cells/mL, and (a, +) 0 wt%, (b, m) 0.05 wt%, (c, A) 0.10 wt% and (d, o) 0.24 wt% of
Type II collagen.
3.3.5 Effect of Cell Concentration
The seeding density of chondrocytes within the scaffold was also found to be important
in determining the rate of tissue synthesis. The natural chondrocyte concentration in human
cartilage is estimated to be 11-27x106 cells/mL [36]. Therefore, in staying near this range,
cellularities of 20x 106, 50x 106 and 100x106 cells/mL were tested in the HA-Tyr scaffolds.
Figures 3.14-3.15 show that as the cell concentration increased, GAG and collagen production
within the scaffold increased. Higher cellularities were expected to improve construct
composition because the more cells were incorporated, the more means for tissue synthesis. High
cell concentrations have also been shown to promote cell-cell and cell-matrix interactions, which
would be important in maintaining cell phenotype and increasing GAG and collagen production
[37, 38]. Though a high cell concentration would be beneficial in promoting early healing, the
levels of GAG and collagen content for the 100x106 cells/mL constructs approached that of the
50x106 cells/mL constructs by Week 8. This might be due to the increased density of the
construct as matrix components were deposited. The increased density might have prevented
sufficient diffusion of nutrients and oxygen to support cell concentrations as high as 100x106
cells/mL, and therefore impacted the rates of biosynthesis.
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Figure 3.14. GAG production within HA-Tyr/collagen/H 20 2/HRP/chondrocyte constructs with
0.5 wt% of HA-Tyr, 0.05 wt% of Type II collagen, and (+) 20x106 cells/mL, (m) 50x106
cells/mL and (A) 100x106 cells/mL.
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Figure 3.15. (a-c) Masson's Trichrome staining for collagen and (d) quantification of blue
content within HA-Tyr/collagen/H 202/HRP/chondrocyte constructs with 0.5 wt% of HA-Tyr,
0.05 wt% of Type II collagen, and (a, 0) 20x 106 cells/mL, (b, m) 50x 106 cells/mL and (c, A )
100x 106 cells/mL.
3.3.6 Effect of Material on Cartilage Regeneration
To compare the HA-Tyr system to other scaffold materials, chondrocytes were seeded in
various commonly used natural biomaterials for cartilage tissue engineering. An HA-Tyr
concentration of 0.5 wt% and Type II collagen concentration of 0.05 wt% was chosen because it
showed the best GAG and collagen production. Agarose and alginate were selected based on
previous studies showing positive results for cartilage phenotype and matrix production [39].
Helistat® sponges are commercially available Type I collagen scaffolds, and were chosen
because they are clinically used and have been investigated for implantation in joint defects [40].
Figure 3.16 shows that GAG production within agarose, alginate and HA-Tyr were comparable
throughout the 8 weeks; for most time points, the differences were not statistically significant (p
< 0.05). In contrast, Figure 3.17 illustrates that collagen levels were greater in HA-Tyr scaffolds
than in alginate and agarose. Similarity in GAG production was not unexpected since all three
materials are linear polysaccharides with similar chemical structures. Collagen production, on
the other hand, might be more sensitive to the specific polymer composition of the scaffold, and
HA-Tyr, being native to cartilage, might have been more conducive to collagen synthesis.
In contrast, GAG production within the Helistat® sponge was lower than that of the other
scaffolds and decreased over time. This was likely due to the fact that this scaffold was made up
of Type I collagen, as opposed to Type II collagen of which articular cartilage is mainly
composed. As previously shown, the chondrocytic phenotype tended to be less stable in Type I
than in Type II collagen sponges [13], and this could have led to decreased production of GAG.
In addition, the histological sections in Figure 3.17, although staining heavily for collagen, show
the production of a visibly fibrous matrix that did not have the finely, granular makeup of natural
articular cartilage. It was improbable that these fibers were due to the sponge itself, as the
Helistat® sponge has been known to degrade subcutaneously in rats within 8 weeks. Since the
GAG content and structure of articular cartilage have been known to be critical to its mechanical
properties and load-bearing function, these results suggested that the Helistat® sponge might not
be optimal for articular cartilage production.
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Figure 3.16. GAG production within constructs of (+) HA-Tyr/collagen/H 20 2/HRP, (m) agarose,(A) alginate and (o) Type I collagen, seeded with 50x 106 cells/mL.
d W~k' R
o
40
- 20
o.0
m 0
0 2 4 6 8
Time (weeks)
Figure 3.17. (a-d) Masson's Trichrome staining for collagen
content within constructs of (a, +) HA-Tyr/collagen/H 20 2/HRP,
and (d, o) collagen, seeded with 50x 106 cells/mL.
and (e) quantification of blue
(b, a) agarose, (c, A) alginate
33.7 Effect of Liposome Incorporation
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HRP-loaded liposomes were synthesized as described in Chapter 2 [41] and added to an
HA-Tyr/collagen/H 20 2/chondrocyte solution. Scaffold formation was then induced by heating
the mixture to 370 C, as a result of which HRP was released to initiate crosslinking. HA-
Tyr/collagen/H 20 2/HRP liposome/chondrocyte constructs were compared in vivo to HA-Tyr/
collagen/H20 2/HRP/chondrocyte and HA-Tyr/collagen/H 20 2/HRP/blank liposome/chondrocyte
constructs, keeping the total amounts of HRP constant. Figure 3.18 shows that the GAG
production in the presence of HRP-loaded liposomes or blank liposomes was comparable to that
of constructs without liposomes. The histological sections in Figures 3.19 also confirmed that
collagen content was equivalent in all three constructs. This illustrated that the liposomes or by-
products of lipid degradation did not result in cytotoxicity, and that the manner in which HRP
was delivered did not affect the matrix production.
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Figure 3.18. GAG production within
wt% of HA-Tyr, 0.05 wt% of Type II
blank liposomes + HRP and (o) HRP.
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Figure 3.19. (a-c) Masson's Trichrome staining for collagen and (d) quantification of blue
content within HA-Tyr/collagen/H 20 2/chondrocyte constructs with 0.5 wt% of HA-Tyr, 0.05
wt% of Type II collagen, 50x 106 cells/mL, and (a, +) HRP liposomes, (b, o) blank liposomes +
HRP and (c, A) HRP.
3.3.8 Injection Studies
In order to test the effect of injecting the scaffold, an HA-Tyr/collagen/H 202/HRP
liposome/chondrocyte precursor solution was injected subcutaneously in a mouse model. Figures
3.20-3.21 show that by Week 8, GAG production within the constructs was - 1.2% of the wet
weight, and that the collagen content measured by histomorphometry was - 35% that of natural
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articular cartilage. These results were comparable to those shown in Section 3.3.7, where
constructs of the same composition were implanted rather than injected.
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GAG production within HA-Tyr/collagen/H 20 2/HRP liposome/chondrocyte
0.5 wt% of HA-Tyr, 0.05 wt% of Type II collagen, and 50x 106 cells/mL.
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Figure 3.21. (a) Masson's Trichrome staining for collagen and (b) quantification of blue content
within HA-Tyr/collagen/H20 2/HRP liposome/chondrocyte constructs with 0.5 wt% of HA-Tyr,
0.05 wt% of Type II collagen, and 50x 106 cells/mL.
3.4 Summary
-I
The potential of the HA-Tyr system as a cartilage tissue engineering scaffold was
demonstrated in this study. Chondrocytes were isolated from porcine joints, and encapsulated
within HA-Tyr hydrogels, which were then implanted or injected subcutaneously in SCID mice.
Cartilaginous tissue was produced, as confirmed by measuring the GAG content within the
constructs and staining for chondrocyte morphology, GAG and collagen. After 8 weeks, the
GAG content was found to reach - 1.2 wt%, while histological sections of harvested constructs
illustrated that the cells could maintain their characteristic rounded morphology and produce -
40% of the collagen content in articular cartilage. Immunohistochemistry further confirmed that
this collagen was mainly composed of Type II collagen, which was characteristic of articular
cartilage. As discussed in Chapter 1, one disadvantage of current therapies is that reparative
tissue produced is often composed of Type I collagen, characteristic of fibrocartilage, which has
inferior mechanical properties and therefore durability [3, 42, 43]. The high content of Type II
collagen in our HA-Tyr constructs showed the potential of this system in producing articular
cartilage, which could better restore joint function and relieve pain.
Several parameters were shown to be important to increasing the tissue generated. An
increase in degradation rate, for example, was found to improve tissue production. In order to
modulate degradation rate, the HA-Tyr concentration was varied, while maintaining the total HA
concentration. As the HA-Tyr concentration decreased, the crosslink density decreased, the
degradation rate increased and more GAG and collagen were produced. This was evidenced in
both histological sections and quantitative GAG measurements. The benefit of rapid degradation
could be associated with (i) more room for cells to secrete matrix components, (ii) improved
diffusion of nutrients and oxygen through the scaffold, (iii) dynamic pore reduction, and (iv)
positive signaling to cells from degradation by-products.
However, a construct that was less crosslinked would be softer and more likely to be
damaged in vivo. Therefore, the incorporation of collagen was studied to strengthen the scaffold,
while maintaining rapid degradation. Since negatively charged HA and positively charged
collagen could form a polyion complex, the presence of collagen increased the mechanical
strength of the construct, as evidenced by the increase in G'. At a collagen concentration of 0.5
wt%, G' more than doubled, while the degradation rate in hyaluronidase did not change
substantially. At collagen concentrations exceeding 0.5 wt%, however, phase separation became
visible and G' began to drop. Implanted HA-Tyr/collagen/H 20 2/HRP/chondrocyte constructs
showed a parallel trend, where a collagen concentration of 0.05 wt% provided more rapid GAG
production and induced greater collagen content, likely due to the positive signaling from the
Type II collagen. Higher collagen concentrations, however, resulted in poor matrix production
and even cell death, due to the excess acetic acid in which the collagen was dissolved.
An increase in cell concentration also enhanced cell-cell and cell-matrix interaction, and
improved matrix production, particularly at short times. By Week 8, however, as the construct
became denser, diffusion of nutrients and oxygen through the construct might not have been
sufficient to support a cell concentration as high as 10x 106 cells/mL, and the GAG and collagen
contents approached that of the 50x 106 cells/mL constructs, indicating a decrease in biosynthesis
rate.
HA-Tyr was compared to several other natural polymers that have been commonly
utilized for cartilage regeneration. It was shown that GAG production within HA-Tyr constructs
was comparable to that of agarose and alginate, while collagen production was higher in HA-Tyr
than in alginate and agarose. The Type I collagen Helistat® sponge, on the other hand showed
lower GAG production than HA-Tyr, agarose and alginate, and led to a visibly fibrous matrix,
unlike that of articular cartilage.
Constructs were also created by adding thermoresponsive HRP-encapsulated liposomes
to an HA-Tyr/collagen/H 202/chondrocyte solution, and heating the mixture to 370 C. By
comparison with constructs created with blank liposomes+HRP and with only HRP, it was
shown that the liposomes were not toxic and that the temperature-induced release of HRP from
liposomes did not affect the matrix production.
An HA-Tyr/collagen/H20 2/HRP liposome/chondrocyte precursor solution was also
injected subcutaneously in a mouse model, and it was shown that GAG and collagen production
were comparable to that in constructs that were implanted. This suggested that in situ scaffold
formation, with the additional benefit of minimally invasive administration, could be as effective
in matrix production as the implantation of a pre-formed construct.
This chapter demonstrates that the HA-Tyr system, including the incorporation of
thermosensitivity through liposomes, has great potential as a scaffold for cartilage repair. The
next chapter describes the incorporation of growth factors to further improve cartilage matrix
synthesis.
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Chapter 4 - Incorporation of PLGA-HAP Composite Particles for the Controlled Release
of TGF-P1 and IGF-1
4.1 Introduction
In the last chapter [1], it was demonstrated that the hyaluronic acid-tyramine (HA-Tyr)
scaffold has great potential for cartilage tissue engineering. Since biochemical signals are potent
modulators of cellular activity, stimulating proliferation, migration, adhesion, differentiation and
gene expression [2, 3], the goal of this chapter is to incorporate the controlled release of growth
factors so as to further enhance cartilage production.
4.1.1 Chondrogenic Effects of TGF-fl1 and IGF-1
Growth factors are integral in the development and maintenance of cartilage [4]. Insulin-
like growth factor (IGF-1), a protein hormone, is synthesized locally by chondrocytes and stored
in the extracellular matrix (ECM) of articular cartilage [5]. It is known to stimulate cell division,
and is considered to be the main anabolic factor in cartilage [3, 6, 7]. Moreover, it has been
shown to inhibit chondrocyte apoptosis induced by stresses, such as ECM degradation or
compression [8]. In engineered constructs, the addition of IGF-1 can significantly increase
biosynthesis level [9 ]. Medium supplemented with IGF-1, for example, increased GAG
production up to fivefold in vitro in chondrocyte-seeded poly(glycolic acid) (PGA) scaffolds [10].
In vivo, IGF-1-loaded gelatin microparticles coencapsulated with chondrocytes in an
oligo(poly(ethylene glycol) fumarate) scaffold were shown to improve neo-surface repair in full
thickness defects in rabbit joints [11 ].
Transforming growth factor type-p31 (TGF-31) is also known to be a potent chondrogenic
inducer, and is present in high concentrations in articular cartilage [6, 12]. It regulates the
proliferation and expression of the differentiated phenotype of chondrocytes [3], and has been
shown to induce the cartilaginous phenotype in rat mesenchymal stem cells [13]. Several studies
have shown the ability of TGF-3 I to induce increased tissue synthesis in vitro and in vivo [5, 6,
10, 14, 15 ]. For example, TGF-P1 added to culture medium in vitro increased collagen
production by chondrocytes in PGA scaffolds [10], and increased cell proliferation and matrix
production in fibrin matrices [6]. In vivo, it has been reported that successive injections of TGF-
l31 stimulated proteoglycan synthesis in cartilage-depleted murine joints [15].
4.1.2 Controlled Release
In natural tissue development and healing, molecular signals and cellular responses
unfold in time [18], where cells differentiate and produce tissue in response to the sequence and
concentrations of cytokines. Therefore, in the delivery of growth factors within tissue engineered
constructs, the gradient as well as absolute concentration at each time point are important
considerations for achieving the correct cell phenotype and for effective matrix synthesis.
Moreover, because tissue development often takes place over the course of several weeks,
growth factors should be delivered over a prolonged period. It has been shown that the direct
injection of growth factors into defect sites is generally ineffective, as proteins either rapidly
diffuse out of the site or are digested by enzymes [16]. Similarly, the direct encapsulation of
IGF-1 and TGF-J31 with chondrocytes in PEG-based hydrogels showed no improvement in ECM
production over the control in vitro [5].
In order to address these issues, various methods of delivery have been studied, including
the incorporation into polymer scaffolds and encapsulation within polymer particles [2, 11, 17].
In these systems, the duration, magnitude and rate of release can be determined by parameters,
such as growth factor loading, and carrier degradation rate, porosity and particle size [18].
Furthermore, since growth factors often have short half-lives, the carrier can serve as a barrier to
protect them from the environment, thereby prolonging bioactivity [4].
4.1.3 PLGA-HAP Nanocomposite Microparticles
Double emulsion processing is a common technique for the synthesis of polymeric
microparticles. Particles are synthesized by adding an aqueous solution containing the
therapeutic agent, e.g. growth factors, to an organic phase and agitating to form a water-in-oil
(W/O) emulsion, which is then added to water and again agitated to create a water-in-oil-in-
water (W/O/W) emulsion. Particles are subsequently formed around the growth factor as the
organic phase is removed either by evaporation or extraction [19]. However, since surface
proteins are loosely associated with the polymer, these particles tend to exhibit a high initial
burst, limiting the period over which the growth factor is released at therapeutic levels.
Furthermore, although parameters, such as polymer molecular weight, surfactant type, and
addition of hydrophilic or hydrophobic agents, have been studied to control release kinetics,
results have shown that the effects of these parameters can be unpredictable [20, 21, 22, 23].
In order to address these issues, Yong et al. of our group have developed a solid-in-oil-in-
water (S/O/W) processing technique to synthesize apatite-polymer nanocomposite microparticles
(Figure 4.1) [24]. In this system, proteins are pre-adsorbed onto hydroxyapatite (HAP), the
mineral component of bone, which has been shown to have a high affinity for proteins [25, 26].
The protein-apatite complex is then suspended in an organic poly(lactic-co-glycolic acid) (PLGA)
solution to form a solid-in-oil suspension, which is added to an aqueous solution and
homogenized to create a S/O/W emulsion. By evaporating off the organic phase, microparticles
composed of apatite-protein complexes dispersed within PLGA are formed. As PLGA degrades
via hydrolysis, the acidic by-products would cause the dissolution of the apatite substrate and
release of the protein. This method has shown versatility in protein delivery, as well as control
over initial burst and growth factor release rate. This system was therefore applied for the
controlled release of IGF-1 and TGF-11 in this study so as to enhance cartilage production.
Figure 4.1. Schematic of the S/O/W method for preparing PLGA-HAP nanocomposite
microparticles loaded with growth factor.
4.2 Experimental
4.2.1 Synthesis ofHydroxyapatite
Nanocrystalline HAP was synthesized by the method developed by Ahn et al [27].
Briefly, equal volumes of calcium nitrate (8.3 mM in water) and ammonium phosphate (5 mM in
water) were combined and aged for 2 days at room temperature. The precipitate was washed with
solutions of decreasing pH and two ethanol washes. The gel was then dried under ambient
conditions overnight, and further dried at 1200 C for 24 h. The dried cake was then ground with a
heated mortar and pestle, and calcined at 5000 C for 2 h (ramp rate = 40C/min). The resulting
powder was sieved through a 45-tm mesh for uniformity. Calcium nitrate and ammonium
phosphate were purchased from Sigma.
Powder X-ray diffraction (XRD) patterns were obtained with a Siemens D5000 0-0
diffractometer (45 kV, 40 mA, Cu Ka). The major peaks at 25.880, 31.770, 32.200, 32.900 and
39.820, corresponding to (002), (211), (112), (300) and (310) diffractions, were used to verify the
pure apatitic phase. The grain size was calculated to be 21 nm from the width of the <002> peak.
4.2.2 Protein Adsorption
To adsorb the protein of interest onto HAP's surface, the protein solution was added to
UV-sterilized HAP powder, and the suspension was stirred at room temperature for 8 h. Typical
adsorption was performed with 50 mg of HAP in 5 mL of cell culture grade water, and either 120
p~L of TGF-31 (10 gg/mL in 1 mg/mL of bovine serum albumin (BSA) in 4 mM hydrochloric
acid (HC1)) or 800 iLL of IGF-1 (100 pg/mL in 1 mg/mL of BSA in phosphate buffered saline
(PBS)). Water was then removed by freeze drying.
Unadsorbed protein was removed by centrifuging the protein-apatite complex (20,000g,
10 min) prior to freeze drying; the supernatant was then removed and tested by ELISA to
measure protein concentration. TGF-01, IGF-1, TGF-P31 ELISA kits, and IGF-1 ELISA kits were
purchased from R&D Systems. HC1, BSA and PBS were purchased from Sigma-Aldrich.
4.2.3 Synthesis ofNanocomposite Microparticles
Microparticles were aseptically synthesized as described by Yong et al [24]. In brief,
protein-apatite complex (20 mg) was suspended in a sterile-filtered PLGA dichloromethane
(DCM) solution (250 mg in 1.5 mL). This mixture was then added to 50 mL of steam-sterilized
0.1 wt% methyl cellulose. The emulsion was homogenized (8000 rpm, 2 min) and then stirred at
300 C for 3 h to evaporate DCM. Methyl cellulose was washed off with 3 centrifugations (500
rpm, 1 min) with sterile water. Water was removed by freeze drying. PLGA was purchased from
Lakeshore Biomaterials, methyl cellulose was purchased from Alfa Aesar, and DCM was
purchased from Sigma.
4.2.4 Release Studies
Release studies were conducted in complete F-12 medium (supplemented with 10% of
fetal bovine serum (FBS), 0.1 M of non-essential amino acids, 0.5 tig/mL of fungizone, 1 wt% of
penicillin-streptomycin, and 0.4 mM of L-proline) at 370 C, at a particle concentration of 10
mg/mL. At each time point, the solution was centrifuged (2500g, 1 min), and the supernatant was
removed. TGF-31 and IGF-1 concentrations in the supernatant were then tested by ELISA.
Release studies were performed in duplicates. The F-12 medium, non-essential amino acids and
fungizone were purchased from Invitrogen, and penicillin-streptomycin and L-proline were
obtained from Sigma-Aldrich.
For total protein release studies, IGF-1 and TGF-p 1 microparticles were synthesized such
that the total protein loading was equal in both types of microparticles. Microparticles were
synthesized as described in Section 4.2.3, except with apatite-protein complexes, where
adsorption was carried out with 50 mg of apatite and 80 ptg of each protein. Total protein release
studies were performed as described above, except in an N,N-bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES) buffer (pH = 7.4). The supernatant was tested for the total
protein concentration by the Coomassie assay. Release studies were conducted in duplicates. The
Coomassie dye was purchased from Pierce Biochemicals, and BES was purchased from Sigma-
Aldrich.
4.2.5 Turbidity Measurements
The effect of pH on IGF-1 and TGF-p1 precipitation was measured by incubating IGF-1
(250 jtg/mL) and TGF-P1 (100 g/mL) in HCI/NaOH solutions of varying pH for 24 h at 370C.
The absorbance of each solution was then measured at 450 nm.
4.2.6 Particle Size
Environmental scanning electron microscopy (ESEM) images of the microparticles were
taken with an FEI/Philips XL30 FEG. The size of the microparticles was calculated as the
number average diameter of at least 100 particles.
4.2.7 Chondrocyte Isolation
Chondrocytes were isolated from the articular cartilage of the femur, patella and tibia of
pig legs (5-6 months old) that were obtained from the local abattoir. The tissue was cut into
small pieces (1 mm3), and digested in a 0.2 wt% Type 2 collagenase solution (in F-12 medium
supplemented with 0.1 M of non-essential amino acids, 0.5 pg/mL of fungizone, 1 wt% of
penicillin-streptomycin, and 0.4 mM of L-proline) at 370 C for 12 h. The cell solution was then
filtered through a 100-pm strainer and centrifuged (8000g, 10 min) twice with PBS. The
collagenase was purchased from Worthington Biochemical.
4.2.8 Subcutaneous Implantation of Particle Constructs In Vivo
HA-Tyr was synthesized as described in Chapter 2 [28]. For the Blank Particle, IGF-1
and TGF-31 Release Rate and Combination Studies (Sections 4.3.3-4.3.6), a HA-Tyr
concentration of 0.8 wt% was used, while a HA-Tyr concentration of 0.5 wt% was used for the
Dosage Study (Sections 4.3.7). Microparticles and porcine chondrocytes (50 x 106 cells/mL)
were suspended in a sterile-filtered HA-Tyr (dissolved in complete medium) and H20 2 (5 wt%, 5
itL per 25 mg of HA-Tyr) solution. 50 pL of the HA-Tyr/H 20 2/chondrocyte/particle solution
were combined with 5 tL of horseradish peroxidase (HRP) (0.125 mg/mL), and placed in a mold
to create a cylindrical gel with a diameter of 8 mm and a thickness of 1 mm. The gels (n = 6)
were then implanted subcutaneously in the dorsum of SCID mice, which were sacrificed at
weeks 2, 4 and 8. Chondrocytes used for implantation were encapsulated immediately post-
harvest, and each experiment, i.e. each graph shown, was conducted with one set of
chondrocytes harvested from an individual pig.
4.2.9 Injection Study
Liposomes were aseptically synthesized as described in Chapter 2 [28] with 60 mg/mL of
lipid (DPPC:DMPC weight ratio = 2.3), 2 mg/mL of HRP, 30 min of sonication, -200 C freezing,
and rehydration volume ratio = 0.1, and were washed with 0.1 M of CaCl2. Liposomes were
combined at 30 jiL/mL (with a HRP activity of 90 Units/mL of liposome) with a solution of HA-
Tyr (0.5 wt%), Type II collagen (0.05 wt%), H20 2 (5 wt%, 4 tL/mL), chondrocytes (50 x 106
cells/mL), 60 mg/mL of IGF- -loaded 24 kDa PLGA-HAP nanocomposite microparticles and 20
mg/mL of TGF-pl-loaded 6 kDa PLGA-HAP nanocomposite microparticles. The precursor
solution (100 pL, n = 6) was then injected subcutaneously in SCID mice with a 21-gauge needle,
and harvested at weeks 2 and 4.
4.2.10 GAG Quantification
To evaluate GAG production (n = 4), constructs were sonicated with a probe-tip sonicator
for 40-60 sec, and then digested in papain (0.125 mg/mL in 100 mM of PBS solution, 10 mM of
ethylenediaminetetraacetic acid (EDTA) and 10 mM of cysteine) at 600 C for 15 h. Digested
constructs were filtered through a 0.45-tm syringe filter, and the GAG concentration was
calorimetrically determined by the Blyscan dimethylmethylene blue assay. GAG content was
then calculated as a percentage of the wet weight of the harvested constructs. Papain was
purchased from Worthington Biochemical, PBS was purchased from EMD Biosciences, EDTA
and cysteine were purchased from Sigma-Aldrich, and the Blyscan kit was purchased from
Biocolor.
In order to reflect the degree of improvement due to the growth factor-loaded
microparticles in each experimental group, GAG content was normalized to the control group
that did not contain any particles at the final time point. For the Blank Particle, IGF-1 and TGF-
pl Release Rate and Combination Studies (Sections 4.3.3-4.3.6), GAG production for control
constructs was 0.7-0.9% of the wet weight at Week 8. For the Dosage Study, control constructs
had a GAG content of 1.0% of the wet weight at Week 8. For the Injection Study, GAG content
in the control constructs was 0.9% of the wet weight at Week 8.
4.2.11 Histology and Histomorphometry
Harvested constructs (n = 2) were fixed in neutral bufferd formalin for at least 24 h. The
constructs were then paraffin-embedded and stained with Masson's Trichrome (Richard-Allan
Scientific).
Histomorphometry was conducted on sections stained with Masson's Trichrome as a
measure of collagen content. Digital images were acquired at the same brightness and exposure
time on an Olympus DP71 camera mounted on an Olympus BX51 microscope, and on a Nikon
DXM1200 camera mounted on an Olympus BX50 microscope. Images were then split into red,
green and blue (RGB) planes on Image J software, and the data were loaded onto Matlab. To
measure the blue intensity of the sections, a method similar to that developed by Martin et al.
was employed [29]. For each pixel, the blue fraction, BF, was defined as BF = B/(R+G+B). BF
was then normalized to BF,N, where BF,N was set to 0 if BF < 0.38 and if R/G < 0.98. This
eliminated pixels that were not stained blue or were stained purple (the nuclei). All other pixels
1 0.38
were proportionally scaled from 0 to 1, i.e. BF,N - BF-- . The blue content for
1-0.38 1-0.38
each pixel was then calculated as Bc = BF*BF,N, and the blue content of the image (Bc) was
calculated as the average of all pixels in the image. Results were reported as a percentage of the
blue content of natural porcine articular cartilage stained at the same time, in order to account for
variations in staining procedure and reagents. At least 3 sections of each sample were stained,
and 4-5 pictures were taken of each section. Images shown represent the average.
4.2.12 Statistics
Graphs of particle size and GAG and collagen contents are depicted as mean ± standard
deviation. One- or two-factor analysis of variance (ANOVA) was conducted to determine
whether significance existed at p < 0.05. For GAG and collagen production, Tukey post hoc
analysis was also conducted to determine whether there was significance at p < 0.05 between
experimental groups. Calculations were performed on Matlab.
4.3 Results and Discussion
4.3.1 Adsorption of TGF-f1I and IGF-1 onto Apatite
The adsorption capacity of IGF-1 and TGF-f31 by HAP was evaluated by adding 2, 5 or
10 gLg of each protein onto 5 mg of apatite in 1 mL of water, and measuring the protein
concentration remaining in the supernatant after 8 h of stirring. According to the R&D Systems
product specifications, ED50(IGF-1) = 0.3-1.5 ng/mL, and ED50(TGFI3-1) = 0.04-0.2 ng/mL, where
ED5o is the effective dose observed to achieve a specific effect on 50% of the cell or animal
population. Therefore, protein quantities above 10 gg were not tested. Figures 4.2-4.3 show that
the majority of the growth factor added (- 99% of IGF-1 and - 98% of TGF-31) was adsorbed
onto the apatite surface, demonstrating the high affinity between the proteins and HAP, and the
efficiency of adsorption.
The IGF-1-loaded PLGA-HAP nanocomposite microparticles studied in the following
sections were prepared with 1.6 pg of IGF-1 adsorbed/mg of HAP, while TGF-P3 l-loaded PLGA-
HAP nanocomposite microparticles were prepared with 0.024 pg of TGF-P1 adsorbed/mg of
HAP. Although previous studies have shown that nanocrystalline HAP has an adsorption
capacity of 159 d 0.8 tg of BSA/mg of HAP [24] and that the particles could potentially be
loaded with higher concentrations of each growth factor, a higher loading was not examined as it
might have dramatically decreased the working range of particle concentrations. Excessively low
particle concentrations would have led to sparse particle distribution, and therefore less
homogeneous growth factor distribution within the construct. In addition, a small number of
microparticles might not have allowed for a representative sample within each scaffold.
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Figure 4.2. Adsorption of IGF-1 onto nanocrystalline HAP (y = 0.99x).
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Figure 4.3. Adsorption of TGF-31 onto nanocrystalline HAP (y = 0.98x).
4.3.2 Effect of Polymer Molecular Weight on Protein Release and Particle Size
The release of TGF-P1 and IGF-1 from the microparticles was studied as a function of
the PLGA molecular weight (MW). As shown in previous studies by Yong et al., as the MW
decreased, the rate of polymer degradation and generation of lactic and glycolic acid increased,
leading to an increase in protein release. This is demonstrated in Figure 4.4 for both IGF-1 and
TGF-pl1. Although the shapes of the release profiles differed between the two proteins, lower
MW resulted in the more rapid release of each protein. Higher MW's, on the other hand, resulted
in more prolonged, gradual and linear release.
It should be noted that a lower initial burst of TGF-p 1 was measured with lower MW
particles, counter to that seen at other time points and to that observed with IGF-1 or BMP-2 [24].
As MW decreased and degradation rate increased, the release rate and initial burst were expected
to increase. Figure 4.5 shows the release of total protein, which includes the carrier protein BSA,
from the particles. As MW decreased, the initial burst of total protein did increase. This was
opposite to that measured by ELISA (Figure 4.4b), which was only a measure of the TGF-PI1
concentration. Therefore, protein release did increase as MW decreased, but TGF-P1, itself, was
released more slowly. Turbidity measurements in Figure 4.6 show that TGF-P1 precipitates out
of solution at pH < 2, and given that the pH within PLGA microspheres could fall below 1.5 [30],
it was likely that at short times, TGF-P13 was desorbed from the apatite, but precipitated within
the microparticles and was therefore not released from the microparticles. This might be
particularly true for the low MW particles, which might have begun to degrade abruptly upon
addition to solution and even during synthesis, generating large amounts of acid within the
microparticles. This trend was not observed with IGF-1 since IGF 1 remained soluble at pH's as
low as 1.
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Figure 4.5. Total (a) BSA and IGF-1 and (b) BSA and TGF-31 protein release from PLGA-HAP
nanocomposite microparticles with PLGA MW's of (*) 6 kDa, (m) 13 kDa, and (A) 24 kDa.
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Figure 4.6. Turbidity of (0) IGF-1 and (*) TGF-31 solutions as a function of pH.
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Figure 4.7 shows that as the PLGA MW increased, there was a statistically significant (p
< 0.05) increase in the size of the microparticles. During synthesis, an increase in MW increased
the viscosity of the PLGA/DCM solution, making the oil droplets more difficult to break up
despite homogenization, and resulting in larger particles. Therefore, release from higher MW
microparticles was slower likely due to a longer diffusion time, as well as the slower polymer
degradation rate.
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Figure 4.7. (a) Size (determined by ESEM) of PLGA-HAP nanocomposite microparticles
containing (*) IGF-1 and (A) TGF-31, prepared with different PLGA MW's. (b-d) ESEM of
PLGA-HAP nanocomposite microparticles with PLGA MW's of (a) 6 kDa, (b) 13 kDa, and (c)
59 kDa.
4.3.3 Effect of Blank Particles In Vivo
Blank microparticles were encapsulated in HA-Tyr/H20 2/HRP/chondrocyte hydrogels
and implanted subcutaneously in mice to test for either positive or negative effects of the
microparticles on chondrocyte matrix synthesis, measured by GAG production. Figure 4.8 shows
the effect of PLGA MW and microparticle concentration on GAG production. At either 10 or 40
mg/mL, and at 6, 13 or 24 kDa, the microparticles did not have a negative effect on GAG
production. By two-way ANOVA, at 10 mg/mL of microparticles, there was no significant
WI I 25-
difference in treatments. However, there was a significant difference (p < 0.05) at 40 mg/mL; a
slight positive effect was observed due to the presence of the microparticles. Nevertheless, from
the post hoc test, only the 6 kDa microparticles showed a significant difference (p < 0.05) over
the control over the 8-week period, increasing GAG production by 1.1-fold at Week 8. This
positive effect might have been due to the generation of acids from microparticle degradation,
which subsequently led to an increase in HA hydrolysis and thereby an increase in the
degradation rate of the scaffold. In Chapter 3 [1], it was shown that increasing scaffold
degradation rate improved chondrogenesis.
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Figure 4.8. Increase in GAG production within HA-Tyr/H20 2/HRP/chondrocyte constructs with
(a) 10 mg/mL and (b) 40 mg/mL of PLGA-HAP nanocomposite microparticles with PLGA
MW's of (+) 6 kDa, (A) 13 kDa, (m) 24 kDa, and (o) with no particles.
4.3.4 Effect of IGF-1 Release Rate on Cartilage Production
In order to study the effect of IGF-1 release rate in vivo, PLGA-HAP nanocomposite
microparticles loaded with IGF-1 and composed of various PLGA MW's were encapsulated
within HA-Tyr/H20 2/HRP/chondrocyte constructs, and implanted subcutaneously in mice.
Figure 4.9 shows that only the 24 kDa microparticles caused a statistically significant increase in
GAG production over the control, resulting in a 1.3-fold increase at Week 8. The blue content of
the sections stained with Masson's Trichrome in Figures 4.10 were calculated as a measure of
collagen production within the constructs. It was shown that all constructs containing IGF-1
particles resulted in greater collagen content than sections that only contained cells. At Week 8,
the 13 kDa microparticles induced a 2.1-fold increase in collagen production over the control,
while the 6 and 24 kDa microparticles induced 1.4-fold and 1.5-fold increases, respectively.
Based on GAG and collagen production, the more gradual to medium release of IGF-1 was most
beneficial in this system. Chondrocyte responsiveness to IGF-1 is dependent on the formation of
focal adhesion plaques to the ECM [6]. However, since HA is anionic, it was unlikely that cells
were able to adhere to the scaffold until they, themselves, had deposited sufficient matrix to bind,
a process that could take several days or even weeks. Therefore, the slower release of IGF-1
from the microparticles might have more effectively promoted matrix production.
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Figure 4.9. Increase in GAG production within HA-Tyr/H20 2/HRP/chondrocyte constructs with
40 mg/mL of IGF- -loaded PLGA-HAP nanocomposite microparticles with PLGA MW's of (0)
6 kDa, (in) 13 kDa and (A) 24 kDa, and (o) with no particles.
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Figure 4.10. (a-d) Masson's Trichrome staining for collagen and (e) quantification of blue
content within HA-Tyr/H20 2/HRP/chondrocyte constructs with 40 mg/mL of IGF-1-loaded
PLGA-HAP nanocomposite microparticles with PLGA MW's of (a, *) 6 kDa, (b, m) 13 kDa and
(c, A) 24 kDa, and (d, o) with no particles.
4.3.5 Effect of TGF-fl Release Rate on Cartilage Production
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TGF-pl-loaded PLGA-HAP nanocomposite microparticles were synthesized with 6, 13
or 24 kDa PLGA to achieve different release kinetics. They were co-encapsulated with
chondrocytes in HA-Tyr constructs, which were then implanted subcutaneously in mice. Figure
4.11 shows that the incorporation of TGF-3 1 microparticles increased GAG production (p < 0.05)
within the constructs over that of the control constructs. The 6 kDa microparticles demonstrated
more GAG production than the 13 and 24 kDa microparticles, and achieved a 1.5-fold increase
over the control by Week 8. Figure 4.12 shows that at Week 8, a 1.6-fold increase in collagen
production was found in the 6 kDa microparticles, while the collagen production associated with
the 13 and 24 kDa microparticles was similar to the control. Thus, as shown by both ECM
components, the earlier and higher gradient release of TGF-P1 from the 6 kDa microparticles
increased chondrogenesis more than the prolonged, linear release of TGF-P1 from the higher
MW microparticles.
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Figure 4.11. Increase in GAG production within HA-Tyr/H20 2/HRP/chondrocyte constructs with
10 mg/mL of TGF-pl-loaded PLGA-HAP nanocomposite microparticles with PLGA MW's of
(0) 6 kDa, (m) 13 kDa and (A) 24 kDa, and (o) with no particles.
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Figure 4.12. (a-d) Masson's Trichrome staining for collagen and (e) quantification of blue
content within HA-Tyr/H20 2/HRP/chondrocyte constructs with 10 mg/mL of TGF-31-loaded
PLGA-HAP nanocomposite microparticles with PLGA MW's of (a, +) 6 kDa, (b, m) 13 kDa and
(c, A) 24 kDa, and (d, *) with no particles.
4.3.6 Effect of Protein Combination on Cartilage Regeneration
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IGF-1 and TGF-31 are known to influence the action of one another, in many cases
acting synergistically [2]. Tsukazaki et al. found that combining IGF-1 and TGF-P1 increased
chondrocyte proliferation in vitro and increased DNA synthesis by up to ten-fold [31]. The
sequential delivery of TGF-31 (Days 3-10) and IGF-1 (Days 10-28) was also shown to be
effective in promoting first chondrocyte proliferation, and then rapid chondrogenesis and tissue
growth [32]. Therefore, in addition to controlling the release rates of growth factors, the
combination and order of growth factor release are important considerations.
To study this effect, IGF-1-loaded PLGA-HAP nanocomposite microparticles and TGF-
31-loaded PLGA-HAP nanocomposite microparticles with different PLGA MW's (and therefore
release profiles) were co-encapsulated with chondrocytes within HA-Tyr hydrogels, and
implanted subcutaneously. A statistically significant increase in GAG production was observed
with all combinations of IGF-1-loaded microparticles and TGF-l1-loaded microparticles over
that of the control (p < 0.05) (Figure 4.13). According to post hoc analysis, the combination of
IGF-l-loaded 24 kDa microparticles and TGF-l1-loaded 6 kDa microparticles showed higher
GAG content than the other combinations, with a 2.1-fold increase over the control after 8 weeks.
Collagen staining also showed that all combinations induced statistically greater collagen
production (p < 0.05) over the control (Figure 4.14). The combination of IGF-1-loaded 24 kDa
microparticles and TGF-pl-loaded 24 kDa microparticles and the combination of IGF-1-loaded
24 kDa microparticles and TGF-pl-loaded 6 kDa microparticles resulted in the highest increase
over the control, with 3.8-fold and 3.5-fold increases, respectively. With regard to GAG
production, the gradual, linear delivery of IGF-1 combined with the high-gradient release of
TGF-31 was most beneficial, reflecting the results in Sections 4.3.4 and 4.3.5. In terms of
collagen production, this combination also resulted in a significant increase in collagen content,
but slightly more collagen was synthesized with the simultaneous gradual release of both growth
factors.
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Figure 4.13. Increase in GAG production within HA-Tyr/H20 2/HRP/chondrocyte constructs with
40 mg/mL of IGF- -loaded PLGA-HAP nanocomposite microparticles and 10 mg/mL of TGF-
p1-loaded PLGA-HAP nanocomposite microparticles with PLGA MW's of (A) 6 kDa and 6
kDa, (n) 6 kDa and 24 kDa, (+) 24 kDa and 6 kDa, and (o) 24 kDa and 24 kDa, respectively, and
(o) with no particles.
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Figure 4.14. (a-e) Masson's Trichrome staining for collagen and (f) quantification of blue
content within HA-Tyr/H20 2/HRP/chondrocyte constructs with 40 mg/mL of IGF-1-loaded
PLGA-HAP nanocomposite microparticles and 10 mg/mL of TGF-pl-loaded PLGA-HAP
nanocomposite microparticles with PLGA MW's of (a, A) 6 kDa and 6 kDa, (b, m) 6 kDa and 24
2 Weeks R Week.
kDa, (c, *) 24 kDa and 6 kDa, and (d, o) 24 kDa and 24 kDa, respectively, and (e, 0) with no
particles.
4.3.7 Dosage Study
The dosage of growth factors is critical, as the effects of the growth factors can be
dependent on their concentrations [3]. TGF-31, for example, can either induce or inhibit cell
proliferation, depending on its dosage [33]. Furthermore, low concentrations are often ineffective,
while high concentrations can be toxic [2, 4]. To determine the effect of IGF-1 and TGF-01
dosage, HA-Tyr/H20 2/HRP/chondrocyte constructs were implanted with various concentrations
of either IGF-1-loaded 24 kDa PLGA-HAP nanocomposite microparticles or TGF- l-loaded 6
kDa PLGA-HAP nanocomposite microparticles. Dosages of IGF-1-loaded microparticles and
TGF- l-loaded microparticles of 20-60 mg/mL and 5-40 mg/mL, respectively, were evaluated
for GAG and collagen production. The concentrations were chosen such that, when combined,
the total particle concentration would not exceed 100 mg/mL. At 100 mg/mL, the viscosity of the
precursor solution was already high enough that passing it through a 21-gauge needle became
difficult; a higher concentration would make the injection of this system problematic. In addition,
by occupying substantial space within the construct, excessively high particle concentrations
could hinder matrix production.
Figure 4.15 shows that all concentrations of IGF- -loaded microparticles increased GAG
production over the control (p < 0.05). The highest concentration (60 mg/mL) gave rise to the
highest GAG production with a 1.7-fold increase over the control at Week 8. Figure 4.16 shows
that the IGF-l-loaded microparticles also induced greater collagen content than the control. The
higher concentrations of 50 and 60 mg/mL resulted in the most collagen synthesis, 2.5-fold and
2.7-fold greater than the control, respectively, at Week 8.
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Figure 4.15. Increase in GAG production within HA-Tyr/H20 2/HRP/chondrocyte/collagen
constructs with (o) 20 mg/mL, (A) 40 mg/mL, (o) 50 mg/mL and (0) 60 mg/mL of IGF-1-loaded
24 kDa PLGA-HAP nanocomposite microparticles, and (*) with no particles.
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Figure 4.16. (a-e) Masson's Trichrome staining for collagen and (f) quantification of blue
content within HA-Tyr/H20 2/HRP/chondrocyte/collagen constructs with (a, m) 20 mg/mL, (b, A)
40 mg/mL, (c, o) 50 mg/mL and (d, A) 60 mg/mL of IGF-1-loaded 24 kDa PLGA-HAP
nanocomposite microparticles, and (e, *) with no particles.
Figure 4.17 shows that TGF-pl-loaded microparticles gave rise to increased GAG
production over the control (p < 0.05). 20 and 40 mg/mL of TGF-pl-loaded microparticles
induced the greatest GAG synthesis with 1.9-fold and 1.7-fold increases, respectively, at Week 8.
Figure 4.18 also shows that TGF-P1-loaded microparticles induced greater collagen content than
the control. The highest collagen content was associated with the highest particle concentration
of 40 mg/mL, which resulted in a 2.7-fold increase over the control at Week 8.
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Figure 4.17. Increase in GAG production within HA-Tyr/H202/HRP/chondrocyte/collagen
constructs with (m) 5 mg/mL, (A) 10 mg/mL, (o) 20 mg/mL and (+) 40 mg/mL of TGF-1-loaded 6 kDa PLGA-HAP nanocomposite microparticles, and with (0) no particles.
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Figure 4.18. (a-e) Masson's Trichrome staining for collagen and (f) quantification of blue
content within HA-Tyr/H202/HRP/chondrocyte/collagen constructs with (a, m) 5 mg/mL, (b, A)10 mg/mL, (c, o) 20 mg/mL and (d, A) 40 mg/mL of TGF-pl-loaded 6 kDa PLGA-HAP
nanocomposite microparticles, and (e, *) with no particles.
4.3.8 Injection Study
In order to test the effect of injecting the system, 60 mg/mL of IGF-1-loaded 24 kDa
PLGA-HAP nanocomposite microparticles and 20 mg/mL of TGF-pl3-loaded 6 kDa PLGA-HAP
nanocomposite microparticles were combined with an HA-Tyr/H20 2/HRP
liposome/chondrocyte/collagen precursor solution and injected subcutaneously in SCID mice. In
response to the exposure to body temperature, HRP was released from the liposomes and
successfully induced the formation of a hydrogel construct encapsulating the cells and particles.
Particle concentrations were chosen based on the levels of increase in GAG production shown in
Section 4.3.7, whereby 60 mg/mL of IGF-1-loaded 24 kDa microparticles and 20 mg/mL of
TGF-3 pl-loaded 6 kDa microparticles (statistically equivalent to 40 mg/mL of TGF-pl-loaded 6
kDa microparticles) induced the highest GAG content. Precursor solutions containing 40 mg/mL
of IGF-1-loaded 24 kDa microparticles and 10 mg/mL of TGF-l1-loaded 6 kDa microparticles
were also injected, in order to compare the levels of improvement found in Section 4.3.6. As
controls, a precursor solution containing no particles, a precursor solution containing 60 mg/mL
of blank 24 kDa PLGA-HAP nanocomposite microparticles and 20 mg/mL of blank 6 kDa
PLGA-HAP nanocomposite microparticles, and a precursor solution with 40 mg/mL of blank 24
kDa PLGA-HAP nanocomposite microparticles and 10 mg/mL of blank 6 kDa PLGA-HAP
nanocomposite microparticles were also injected.
Harvested constructs showed that the combination of 60 mg/ml of IGF-1-loaded
microparticles and 20 mg/mL of TGF-l1-loaded microparticles and of 40 mg/mL of IGF-1-
loaded microparticles and 10 mg/mL of TGF-l1-loaded microparticles produced statistically
equivalent increases in GAG production, 2.0-fold and 1.9-fold at Week 8, respectively (Figure
4.19). Both combinations also resulted in a 2.1-fold increase in collagen content over the control
at Week 8 (Figure 4.20). These results show that when the particles were combined within these
concentration ranges, improvements to GAG and collagen production were not generally dose-
dependent. In addition, it was found that, at both sets of particle concentrations, the combinations
of IGF-1-loaded microparticles and TGF-pl-loaded microparticles resulted in similar levels of
improvement in GAG and collagen production to that observed with 20 mg/mL of TGF-P31-
loaded microparticles alone (Section 4.3.7). It should also be noted that although particle-
induced increases to collagen production were not as high as that observed in Section 4.3.6 and
for 60 mg/mL of IGF-1 particles alone (Section 4.3.7), constructs containing 60 mg/mL of IGF-
1-loaded microparticles and 20 mg/mL of TGF-P3 1-loaded microparticles and those containing 40
mg/mL of IGF-1-loaded microparticles and 10 mg/mL of TGF-pl-loaded microparticles
respectively achieved collagen contents of 95±-12% and 92+7% that of natural articular cartilage.
This study showed that growth factor-loaded microparticles could be injected with the precursor
solution to form a construct in vivo, and that growth factors introduced by this method
successfully increased matrix production within the constructs.
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Figure 4.19. Increase in GAG production within HA-Tyr/H20 2/HRPliposome/chondrocyte/collagen constructs with (+) 60 mg/mL of IGF- -loaded 24 kDa PLGA-
HAP nanocomposite microparticles and 20 mg/mL of TGF-1l-loaded 6 kDa PLGA-HAP
nanocomposite particles, (m) 40 mg/mL of IGF-1-loaded 24 kDa PLGA-HAP nanocomposite
microparticles and 10 mg/mL of TGF-P3 l-loaded 6 kDa PLGA-HAP nanocomposite particles, (A)
60 mg/mL of blank 24 kDa PLGA-HAP nanocomposite microparticles and 20 mg/mL of blank 6
kDa PLGA-HAP nanocomposite microparticles, (*) 40 mg/mL of blank 24 kDa PLGA-HAP
nanocomposite microparticles and 10 mg/mL of blank 6 kDa PLGA-HAP nanocomposite
microparticles, and (0) no particles.
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Figure 4.20. (a-e) Masson's Trichrome staining for collagen and (f) quantification of blue
content within HA-Tyr/H 20 2/HRP liposome/chondrocyte/collagen constructs with (a, 0) 60
mg/mL of IGF-1-loaded 24 kDa PLGA-HAP nanocomposite microparticles and 20 mg/mL of
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TGF-pl-loaded 6 kDa PLGA-HAP nanocomposite particles, (b, o) 40 mg/mL of IGF-1-loaded
24 kDa PLGA-HAP nanocomposite microparticles and 10 mg/mL of TGF-l1-loaded 6 kDa
PLGA-HAP nanocomposite particles, (c, A) 60 mg/mL of blank 24 kDa PLGA-HAP
nanocomposite microparticles and 20 mg/mL of blank 6 kDa PLGA-HAP nanocomposite
microparticles, (d, o) 40 mg/mL of blank 24 kDa PLGA-HAP nanocomposite microparticles and
10 mg/mL of blank 6 kDa PLGA-HAP nanocomposite microparticles, and (e, *) no particles.
4.4 Summary
IGF-1 and TGF-P1 were loaded into PLGA-HAP nanocomposite microparticles and
incorporated into scaffolds to enhance cartilage regeneration. The particles were prepared by a
S/O/W emulsion technique, and it was shown that the rate of growth factor release could be
modulated by the PLGA MW. The release of growth factor from the particles was measured by
suspending the particle in complete medium, and measuring the growth factor concentration in
the supernatant over time. It was found that for both growth factors, increases in PLGA
molecular weight decreased the rate of PLGA degradation, and therefore reduced the gradient
and increased the period of release.
The effect of the microparticles themselves was verified by encapsulating chondrocytes
and blank microparticles that did not contain growth factor within HA-Tyr hydrogels, which
were then implanted subcutaneously in mice. The harvested constructs containing 10 mg/mL of
microparticles showed equivalent GAG production to that of the control, while a slightly higher
GAG content was observed in those containing 40 mg/mL of microparticles. This indicated that
the microparticles did not hinder matrix synthesis, but enhanced chondrogenesis to a slight
degree at higher concentrations. This might be attributed to the acidic by-products of particle
degradation, which might have enhanced HA degradation and increased matrix production (as
illustrated in Chapter 3 [1]).
Microparticles loaded with IGF-1 and composed of 6, 13 or 24 kDa PLGA were then
encapsulated within the HA-Tyr hydrogels and implanted subcutaneously. It was found that the
IGF-1-loaded 24 kDa microparticles increased GAG production over the control, while the lower
MW microparticles did not exhibit a statistically significant increase. On the other hand,
histomorphometry of the histological sections stained for collagen showed that all microparticles
increased collagen production within the constructs relative to the control. The 13 kDa
microparticles, with a medium release gradient, resulted in the greatest collagen synthesis. This
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showed that within the HA-Tyr system, the gradual to medium release rates of IGF-1 were more
effective in inducing GAG and collagen production by chondrocytes.
TGF-l1-loaded microparticles composed of 6, 13 or 24 kDa PLGA were also tested in
vivo, and all showed a statistically significant increase in GAG production over the control. The
higher gradient of TGF-pl release from the 6 kDa microparticles resulted in the most GAG
production and the most collagen production. In the HA-Tyr system, the early and rapid release
of TGF-3 1 was most beneficial in inducing greater tissue production.
The effect of multifactor release was then studied by creating HA-
Tyr/H202/HRP/chondrocyte constructs with IGF-1-loaded microparticles and TGF-pl-loaded
microparticles, and implanting them subcutaneously in mice. Various combinations of the
microparticles composed of 6 or 24 kDa PLGA were investigated. It was found that all
combinations resulted in greater GAG production and collagen production than the control. The
combination of IGF-l-loaded 24 kDa microparticles and TGF-pl-loaded 6 kDa microparticles
produced the most GAG. The combination of IGF- -loaded 24 kDa microparticles and TGF-P3 l-
loaded 24 kDa microparticles and the combination of IGF-1-loaded 24 kDa microparticles and
TGF-3P -loaded 6 kDa microparticles showed the most collagen production.
The effect of IGF-1 particle dosage was studied by co-encapsulating 20-60 mg/mL of
IGF- -loaded 24 kDa microparticles with chondrocytes within HA-Tyr constructs, which were
subsequently implanted in vivo. All particle concentrations resulted in a statistically significant
increase in GAG production over the control, with 60 mg/mL giving the highest GAG content at
Week 8. All concentrations were observed to increase collagen content over the control, but 50
and 60 mg/mL showed the greatest collagen synthesis.
TGF-31 dosage was studied by encapsulating chondrocytes with 5-40 mg/mL of TGF-
pl-loaded 6 kDa microparticles within the HA-Tyr hydrogels. All particle concentrations
showed a statistically significant enhancement in both GAG and collagen production over the
control. However, 20 and 40 mg/mL resulted in the highest GAG production, while 40 mg/mL
induced the greatest collagen content.
The HA-Tyr/H 202/HRP liposome/chondrocyte/collagen precursor solution was then
injected subcutaneously with 60 mg/mL of IGF-l-loaded 24 kDa microparticles and 20 mg/mL
of TGF-pl-loaded 6 kDa microparticles. It was shown that in situ scaffold formation could occur
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in the presence of the microparticles. Delivery of the growth factors by this method significantly
improved GAG and collagen production within the constructs by 2.0 and 2.1-fold, respectively,
at Week 8.
This study shows that the delivery of IGF-1 and TGF-131 via PLGA-HAP nanocomposite
microparticles is promising for the enhancement of chondrogenesis in the HA-Tyr system. In
optimizing matrix synthesis, the tunability of the polymer-apatite microparticle system allows for
the incorporation of different growth factors, release kinetics, dosages as well as multifactor
release. Furthermore, it has been shown that the microparticles can be effectively incorporated
into an injectable system for minimally invasive administration.
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Chapter 5 - Recommendations for Future Work
5.1 Study of Scaffolds in Articular Defect Models
In this thesis, an injectable hyaluronic acid scaffold was developed for cartilage tissue
engineering. While the subcutaneous results have been useful in quantifying the effects of
various parameters on cartilage production in vivo, the HA-Tyr system as well as the growth
factor-loaded nanocomposite microparticles should next be tested in an articular defect model.
Although the load-bearing characteristics and cartilage repair rates of larger animal models, such
as dogs, goats or horses, would more closely resemble that of humans, it would be more cost-
effective to conduct initial studies on a smaller animal model, such as rabbits [1, 2]. Joint defects
treated with HA-Tyr/H202/HRP/chondrocyte/microparticle constructs could be compared to
those treated with HA-Tyr/H202/HRP/chrondrocyte, those treated with autologous chondrocyte
implantation (ACI) and those left untreated. Evaluation of healing could be based on filling of
the defect site, integration with the existing tissue, histology, quantification of GAG and collagen
production, mechanical measurements, such as compression or indentation, and signs of
inflammation. Constructs could be harvested and tested for initial healing at shorter time points,
such as 4-8 weeks, and for durability at longer time points, such as 6-12 months.
In addition, while it was shown that the HA-Tyr/H 20 2/HRP liposome/chondrocyte
system was able to form a construct subcutaneously in response to the exposure to body
temperature, the injectability within the joint should also be studied. The gelation time should be
optimized to ensure retention of the precursor solution within the defect site, while preventing
premature gelation ex vivo. Though joint fluid is present, it might be aspirated out temporarily
and replaced after scaffold formation has occurred.
5.2 Exploration of Cell Source
While primary chondrocytes were chosen in this study, mesenchymal stem cells (MSCs),
which have the capability of differentiating to chondrocytes, have also shown the ability to
achieve chondrogenesis under proper culture conditions [3, 4, 5]. MSCs can be derived from the
periosteum, perichondrium, muscles and bone marrow, and would therefore not require the
sacrifice of cartilage from non-load-bearing sites in order to attain chondrocytes. Bone marrow
stromal cells (BMSCs), in particular, are of great interest because they can be aspirated directly
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from bone marrow [3]. MSCs could be cultured in vitro to induce differentiation with the aid of
growth factors, such as TGF-P13, which could be delivered via the PLGA-HAP nanocomposite
microparticles [4, 5, 6]. The cells could be subsequently seeded in scaffolds and introduced into
the defect sites. Alternatively, MSCs might be directly implanted with the scaffold in the defect
site in order to test the scaffold and joint environment's ability to induce differentiation.
Differentiation can be measured by the expression of cartilage-specific markers, such as Type II
collagen, aggrecan and Sox9 [7].
In addition, whether chondrocytes or MSCs, it would be best to test treatments on
different cell sources. Each graph depicting GAG and collagen content in the thesis represented
the results from constructs composed of chondrocytes isolated from one pig. Future experiments
could be designed to test whether the same trends exist for different cells derived from animals
of varying size, age, sex and health.
5.3 Study of Other Growth Factors and Chondrocyte Signaling Pathways
While IGF-1 and TGF-P1 were shown to effectively enhance chondrogenesis, several
other growth factors are also known to regulate the growth and differentiation of cartilage, such
as bone morphogenetic proteins, fibroblast growth factor, platelet-derived growth factor and
cartilage-derived morphogenetic protein [8, 9]. The effects of the release rates, dosages and
combinations, not only on matrix production, but also on the differentiation of MSCs, can be
studied and compared to those of IGF-1 and TGF-P31.
The signaling pathways within chondrocytes and MSCs can also be further studied to
understand the mechanisms behind growth factor upregulation of matrix synthesis and
differentiation and the relationships between the growth factors. This knowledge would aid in
designing the optimal rates and sequences of delivery within future constructs.
5.4 Application to Other Scaffolds
As scaffold composition determines cell-substrate interactions, which in turn affect tissue
synthesis and the actions of growth factors, different types of scaffolds can also be studied.
Liposomes are versatile encapsulating agents, and thermosensitivity may potentially be imparted
to various polymer-crosslinking agent or monomer-catalyst systems, e.g. collagen-
transglutaminase, elastin-lysyl oxidase, and fibrinogen-thrombin [10, 11, 12]. The abilities of
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these scaffold systems to induce cartilage synthesis could be compared to that of the HA-Tyr
system. In addition, the scaffolds could be explored for other applications, such as bone
regeneration, wound healing, drug delivery, or cosmetic soft tissue filling.
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Chapter 6 - Conclusions
A thermally triggered injectable scaffold was developed by utilizing thermoresponsive
liposomes to segregate a crosslinking agent from a polymer. Liposomes were synthesized by a
dehydration-rehydration vesicle method to encapsulate HRP. The HA-Tyr/H 20 2/HRP liposome
precursor solution remained a liquid for several hours at room temperature, and formed a
hydrogel scaffold within minutes when exposed to body temperature. HRP encapsulation and
gelation kinetics were modified by various material and processing parameters, such as lipid
content, HRP loading and composition of wash solution.
In vivo studies showed the potential of the HA-Tyr system as a cartilage tissue
engineering scaffold. Chondrocytes encapsulated within the constructs and implanted
subcutaneously showed significant production of GAG and collagen, including Type II collagen,
which is characteristic of articular cartilage. The effects of crosslink density, Type II collagen
incorporation and cell seeding density on GAG and collagen synthesis were studied.
Subcutaneous injection of the HA-Tyr/H20 2/HRP liposome/chondrocyte/collagen precursor
solution demonstrated the feasibility of thermally triggered scaffold formation, and showed that
injected scaffolds could induce matrix synthesis levels comparable to those that were implanted.
TGF-131- and IGF-l-loaded PLGA-HAP nanocomposite microparticles were synthesized
by a solid-in-oil-in-water emulsion process. The rate of growth factor release could be modulated
by the molecular weight of PLGA. Nanocomposite microparticles co-encapsulated with
chondrocytes within the HA-Tyr scaffolds illustrated the effects of growth factor release rate,
combination and dosage on the enhancement of GAG and collagen synthesis. An HA-
Tyr/H202/HRP liposome/chondrocyte/collagen/microparticle precursor solution was injected
subcutaneously in a mouse model. It was demonstrated that the growth factor-loaded
nanocomposite microparticles could be incorporated into the injectable system, and retained the
ability to significantly increase matrix production.
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